<SEC-DOCUMENT>0001683168-25-007760.txt : 20251024
<SEC-HEADER>0001683168-25-007760.hdr.sgml : 20251024
<ACCEPTANCE-DATETIME>20251024160046
ACCESSION NUMBER:		0001683168-25-007760
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251117
FILED AS OF DATE:		20251024
DATE AS OF CHANGE:		20251024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39126
		FILM NUMBER:		251416107

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>cns_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:CNSP="http://cnspharma.com/20251117">
<head>
     <title>CNS Pharmaceuticals,&#160;Inc. PRE 14A</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_033_CNSP_cnspharma.com_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20251117_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001729427 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000004" name="dei:EntityCentralIndexKey">0001729427</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="xdx2ixbrl0010" name="dei:DocumentType">DEF 14A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cnsp-20251117.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001729427</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-17</xbrli:startDate>
        <xbrli:endDate>2025-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_907_edei--DocumentType_dxL_c20251117__20251117_z4nwmVu1pshe" title="::XDX::DEF%2014A"><span style="-sec-ix-hidden: xdx2ixbrl0010">SCHEDULE 14A</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Amendment No.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Filed by the Registrant <span style="font-family: Wingdings">x</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Filed by a Party other than the Registrant <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td style="width: 97%"><span style="font-size: 10pt">Preliminary Proxy Statement</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt"><b>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Wingdings; font-size: 10pt">x</span></td>
    <td><span style="font-size: 10pt">Definitive Proxy Statement</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt">Definitive Additional Materials</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt">Soliciting Material Pursuant to &#167;240.14a-12</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font-size: 10pt; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20251117__20251117_zeBzarwuUfP9"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000011" name="dei:EntityRegistrantName">CNS
    Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Registrant as Specified In Its Charter)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings; font-size: 10pt">x</span></td>
    <td style="width: 99%; font-size: 10pt"><span style="font-size: 10pt"> &#160;&#160;No fee required.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td style="width: 99%; font-size: 10pt"><span style="font-size: 10pt">&#160;&#160;Fee paid previously with preliminary materials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings; font-size: 10pt">o</span></td>
    <td style="width: 99%; font-size: 10pt"><span style="font-size: 10pt">&#160;&#160;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CNS Pharmaceuticals,&#160;Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2100 West Loop South, Suite 900</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Houston, TX 77027</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(800) 946-9185</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Stockholders of CNS Pharmaceuticals, Inc.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You are cordially invited to attend
the Annual Meeting of Stockholders of CNS Pharmaceuticals,&#160;Inc. on November 17, 2025. The Annual Meeting will begin at 12:00 P.M.
Eastern Standard Time virtually at https://westcoaststocktransfer.com/proxy-CNSP/ where you will be able to listen to the meeting live,
submit questions and vote online.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information regarding each of
the matters to be voted on at the Annual Meeting is contained in the attached Proxy Statement and Notice of Annual Meeting of Stockholders.
We urge you to read the proxy statement carefully. The proxy statement and proxy card are being mailed to all stockholders of record as
of October 10, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because it is important that your
shares be voted at the Annual Meeting, we urge you to complete, date and sign the enclosed proxy card and return it as promptly as possible
in the accompanying envelope, whether or not you plan to attend. Even after returning your proxy, if you are a stockholder of record and
do attend the meeting and wish to vote your shares in person, you still may do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Very truly yours,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CNS Pharmaceuticals,&#160;Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 42%"><span style="font-size: 10pt">/s/ John Climaco</span></td>
    <td style="width: 53%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">John Climaco</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Important Notice Regarding the Availability of Proxy
Materials</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>for the Annual Stockholder Meeting to be Held on
November 17, 2025:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Electronic Copies of the Proxy Statement and our 2024
Annual Report on Form&#160;10-K are available at</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">http://icomproxy.com/cnsp</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CNS Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2100 West Loop South, Suite 900</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Houston, TX 77027</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(800)&#160;946-9185</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>To Be Held November 17, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TO THE STOCKHOLDERS OF CNS PHARMACEUTICALS, INC.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting
of Stockholders of CNS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) will be held virtually at https://westcoaststocktransfer.com/proxy-CNSP/,
on November 17, 2025 at 12:00 P.M. Eastern Standard Time, for the following purposes, as described in the accompanying Proxy Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2026 annual meeting of stockholders of the Company or until such person&#8217;s successor is qualified and elected.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To ratify the appointment of MaloneBailey, LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory resolution to approve executive compensation.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve an amendment to the Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve amendments to the Company&#8217;s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the Company&#8217;s 2020 Stock Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the above proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Only stockholders of record of the Company at the
close of business on October 10, 2025, are entitled to notice of and to vote at the Annual Meeting or any adjournment or postponement
thereof. You will be able to listen to the meeting live, submit questions and vote online at the virtual Annual Meeting. A complete list
of these stockholders will be open for the examination of any stockholder of record at the Company&#8217;s principal executive offices
located at 2100 West Loop South, Suite 900, Houston, TX 77027 for a period of ten days prior to the Annual Meeting. The Annual Meeting
may be adjourned or postponed from time to time without notice other than by announcement at the meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING,
PLEASE SIGN AND DATE THE ENCLOSED PROXY AND RETURN IT IN THE ENVELOPE PROVIDED.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 45%">&#160;</td>
    <td style="width: 55%"><span style="font-size: 10pt">By Order of the Board of Directors,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">CNS PHARMACEUTICALS,&#160;INC.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ John Climaco</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Houston, Texas</span></td>
    <td><span style="font-size: 10pt">John Climaco</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">October 24, 2025</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 6pt"><b><span id="a_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 6pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 96%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 3%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><a href="#a_002"><span style="font-size: 10pt"><b>INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_003">WHY DID YOU SEND ME THIS PROXY STATEMENT?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_004">WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_005">WHO MAY VOTE ON THESE PROPOSALS?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">2</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_006">HOW MANY VOTES DO I HAVE?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_007">WHY WOULD THE ANNUAL MEETING BE POSTPONED?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><a href="#a_008">HOW DO I VOTE WITHOUT ATTENDING THE MEETING?</a></b></p>
</td>
    <td>&#160;</td>
    <td style="text-align: right">3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><a href="#a_009">HOW CAN I VOTE MY SHARES IN PERSON AND PARTICIPATE AT THE ANNUAL MEETING?</a></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</td>
    <td>&#160;</td>
    <td style="text-align: right">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_010">MAY I REVOKE MY PROXY?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_011">WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_012">ARE THERE ANY RIGHTS OF APPRAISAL?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_013">WHO BEARS THE COST OF SOLICITING PROXIES?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_014">WHERE ARE CNS&#8217; PRINCIPAL EXECUTIVE OFFICES?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_015">HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT CNS?</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_016">STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">6</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_017">INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">7</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><a href="#a_018"><span style="font-size: 10pt"><b>GOVERNANCE OF THE COMPANY</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_019">COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_023">RELATED PARTY TRANSACTIONS</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">20</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b><a href="#a_024">PROPOSAL 1: ELECTION OF DIRECTORS</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt"><b><a href="#a_025">PROPOSAL 2: TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt"><b><a href="#a_026">PROPOSAL 3: TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt; text-transform: uppercase"><b><a href="#a_027">PROPOSAL 4: TO VOTE ON A NON-BINDING, ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt"><b><a href="#a_028">PROPOSAL 5: TO APPROVE AN AMENDMENT TO THE COMPANY&#8217;S AMENDED AND RESTATED ARTICLES OF INCORPORATION TO INCREASE THE TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 25,000,000 SHARES TO 300,000,000 SHARES AND THE TOTAL NUMBER OF AUTHORIZED SHARES OF PREFERRED STOCK FROM 416,667 SHARES TO 5,000,000 SHARES</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt"><b><a href="#a_029">PROPOSAL 6: TO APPROVE AMENDMENTS TO THE COMPANY&#8217;S 2020 STOCK PLAN INCLUDING AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE COMPANY&#8217;S 2020 STOCK PLAN</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right">27</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-size: 10pt; text-transform: uppercase"><b><a href="#a_030">PROPOSAL 7: To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve ANY OF THE ABOVE Proposals</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3</span>4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><a href="#a_031"><span style="font-size: 10pt"><b>AUDIT COMMITTEE REPORT</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right">3<span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><a href="#a_032"><span style="font-size: 10pt"><b>AVAILABILITY OF ANNUAL REPORT ON FORM 10-K</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><a href="#a_033"><span style="font-size: 10pt"><b>OTHER PROPOSED ACTION</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><a href="#a_034"><span style="font-size: 10pt"><b>HOUSEHOLDING OF PROXY MATERIALS</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><a href="#a_035"><span style="font-size: 10pt"><b>STOCKHOLDER PROPOSALS AND SUBMISSIONS</b></span></a></td>
    <td>&#160;</td>
    <td style="text-align: right">37</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CNS PHARMACEUTICALS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PROXY STATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANNUAL MEETING OF STOCKHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>To Be Held November 17, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_002"></span>INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_003"></span>WHY DID YOU SEND ME THIS PROXY STATEMENT?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This proxy statement and the enclosed proxy card are
furnished in connection with the solicitation of proxies by the Board of Directors of CNS Pharmaceuticals, Inc., a Nevada corporation,
for use at the Annual Meeting of CNS Pharmaceuticals&#8217; stockholders to be held on November 17, 2025. The Annual Meeting will begin
at 12:00 P.M. Eastern Standard Time virtually at https://westcoaststocktransfer.com/proxy-CNSP/. This proxy statement summarizes the information
you need to make an informed vote on the proposals to be considered at the Annual Meeting. However, you do not need to attend the Annual
Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card using the envelope provided. The
terms &#8220;CNS Pharmaceuticals,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221; refer to CNS Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>WHAT PROPOSALS WILL BE ADDRESSED AT THE ANNUAL MEETING?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We will address the following proposals at the Annual Meeting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2026 annual meeting of stockholders of the Company or until such person&#8217;s successor is qualified and elected.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To ratify the appointment of MaloneBailey, LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory resolution to approve executive compensation.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve an amendment to the Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve amendments to the Company&#8217;s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the Company&#8217;s 2020 Stock Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the above proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>WHO MAY VOTE ON THESE PROPOSALS?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will send this proxy statement, the attached Notice
of Annual Meeting and the enclosed proxy card on or about October 24, 2025 to all stockholders as of October 10, 2025 (the &#8220;Record
Date&#8221;). Stockholders who owned shares of our common stock at the close of business on the Record Date are entitled to vote at the
Annual Meeting on all matters properly brought before the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the Record Date, we had 574,580 shares of issued
and outstanding common stock entitled to vote at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_006"></span>HOW MANY VOTES DO I HAVE?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of common stock is entitled to one vote
on each matter presented at the Annual Meeting. Cumulative voting is not permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_007"></span>WHY WOULD THE ANNUAL MEETING BE POSTPONED?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Annual Meeting will be postponed if a quorum is
not present on November 17, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2026 annual meeting of stockholders of the Company or until such person&#8217;s successor is qualified and elected.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To ratify the appointment of MaloneBailey, LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory resolution to approve executive compensation.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To vote on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve an amendment to the Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve amendments to the Company&#8217;s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the Company&#8217;s 2020 Stock Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the above proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The presence in person or by proxy of at least one-third
of our common stock outstanding as of the Record Date will constitute a quorum and is required to transact business at the Annual Meeting.
If a quorum is not present, the Annual Meeting may be adjourned until a quorum is obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abstentions and broker non-votes are treated as shares
present or represented at the meeting but are not counted as votes cast. Shares held by brokers who do not have discretionary authority
to vote on a particular matter and who have not received voting instructions from their customers are not counted or deemed to be present
or represented for the purpose of determining whether stockholders have approved that matter, but they are counted as present for the
purposes of determining the existence of a quorum at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>HOW DO I VOTE WITHOUT ATTENDING THE MEETING?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vote via Proxy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whether you plan to attend the Annual Meeting or not,
we urge you to complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. Returning the proxy card
will not affect your right to attend the Annual Meeting and vote in person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you properly fill in your proxy card and send it
to us in time to vote, your proxy (one of the individuals named on your proxy card) will vote your shares as you have directed. If you
sign the proxy card but do not make specific choices, your proxy will vote your shares as recommended by the Board of Directors as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR the election of the Board&#8217;s six nominees to our Board of Directors.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR ratification of the appointment of MaloneBailey, LLP as our independent registered public accounting firm for the year ending December 31, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR approval of a non-binding, advisory resolution to approve executive compensation.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR approval of on a non-binding, advisory proposal on the frequency of holding future votes regarding executive compensation.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR approval of an amendment to the Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR approval of amendments to the 2020 Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FOR approval to authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any other matters are presented, your proxy will
vote in accordance with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be
acted on at the Annual Meeting other than those discussed in this proxy statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vote via Telephone</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are a stockholder of record, you may call (619)
664-4780, toll-free in the United States, U.S. territories and Canada, and use any touch-tone telephone to transmit your vote up until
11:59 P.M., Eastern Standard Time, November 16, 2025 (the day before the Annual Meeting). Have your proxy card in hand when you call and
then follow the instructions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vote via Internet</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a stockholder of record, you may use
the Internet to transmit your vote up until 11:59 P.M., Eastern Standard Time, November 16, 2025 (the day before the Annual Meeting).
Visit https://westcoaststocktransfer.com/proxy-CNSP/ and have your proxy card in hand when you access the website and follow the instructions.
You will need your control number and Request ID to vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you hold your shares in &#8220;street name,&#8221;
that is through a broker, bank or other nominee, that institution will instruct you as to how your shares may be voted by proxy, including
whether telephone or Internet voting options are available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>HOW CAN I VOTE MY SHARES IN PERSON AND PARTICIPATE AT THE ANNUAL MEETING?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To participate in the virtual Annual Meeting,
visit&#160;https://westcoaststocktransfer.com/proxy-CNSP/ and enter the control number on your proxy card, or on the instructions that
accompanied your proxy materials. You will need your control number and Request ID to access and vote the Annual Meeting. We recommend
you login to the Annual Meeting at least 15 minutes before the meeting is scheduled to start so that any technical difficulties may be
addressed before the meeting begins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you do not have your control number or Request
ID, contact West Coast Stock Transfer at the phone number or e-mail address below. Beneficial investors who hold shares through a bank,
broker or other intermediary, will need to contact them and obtain a legal proxy. Once you have your legal proxy, contact West Coast Stock
Transfer to have a control number generated. West Coast Stock Transfer contact information is as follows: phone (619) 664-4780 ext. 100,
or email proxy@wcsti.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stockholders will also have the option to listen to
the Annual Meeting by visiting the link below to register:&#160;https://westcoaststocktransfer.com/proxy-CNSP/.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You will not be able to vote or submit questions unless
you register for and log in to the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>MAY I REVOKE MY PROXY?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If you give a proxy, you may revoke it at any time before it is exercised.
You may revoke your proxy in three ways:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-size: 10pt">1.</span></td>
    <td style="width: 95%"><span style="font-size: 10pt">You may send in another proxy with a later date.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">You may notify us in writing (or if the stockholder is a corporation, under its corporate seal, by an officer or attorney of the corporation) at our principal executive offices before the Annual Meeting that you are revoking your proxy.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">3.</span></td>
    <td><span style="font-size: 10pt">You may vote in person at the Annual Meeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><b>Proposal 1: Election of Directors</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A plurality of the eligible votes cast is required
to elect director nominees, and as such, the six nominees who receive the greatest number of &#8220;For&#8221; votes cast by stockholders,
entitled to vote at the meeting, will be elected. A nominee who receives a plurality means he or she has received more &#8220;For&#8221;
votes than any other nominee for the same director&#8217;s seat. Broker non-votes will have no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Proposal 2: Ratification of Appointment
of Independent Registered Public Accounting Firm.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 2 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Proposal 3: To vote on a non-binding,
advisory resolution to approve executive compensation. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 3 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>Proposal 4: To vote on a non-binding, advisory proposal
on the frequency of holding future votes regarding executive compensation. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 4 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Proposal 5: To approve an amendment
to the Company&#8217;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock
from 25,000,000 shares to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000
shares.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 5 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Proposal 6: To approve amendments
to the 2020 Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 6 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Proposal 7: To authorize the
adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual
Meeting or adjournment or postponement thereof to approve any of the proposals.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 7 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Other Business That Is Properly Brought Before the Annual Meeting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you do not give instructions to your bank or brokerage
firm, it will nevertheless be entitled to vote your shares in its discretion on routine matters. However, absent your instructions, the
record holder will not be permitted to vote your shares on a non-routine matter, which are referred to as &#8220;broker non-votes&#8221;,
properly brought before the meeting. Broker non-votes (shares held by brokers that do not have discretionary authority to vote on the
matter and have not received voting instructions from their clients) are not counted or deemed to be present or represented for the purpose
of determining whether stockholders have approved that proposal, but will be counted in determining whether there is a quorum present.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_012"></span>ARE THERE ANY RIGHTS OF APPRAISAL?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is not proposing any action
for which the laws of the State of Nevada, our Amended and Restated Articles of Incorporation or our Amended and Restated Bylaws provide
a right of a stockholder to obtain appraisal of or payment for such stockholder&#8217;s shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_013"></span>WHO BEARS THE COST OF SOLICITING PROXIES?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will bear the cost of soliciting proxies in the
accompanying form and will reimburse brokerage firms and others for expenses involved in forwarding proxy materials to beneficial owners
or soliciting their execution. In addition, our directors, our executive officers and certain of our employees may, without additional
compensation, solicit proxies by mail, in person, by telephone or other electronic means or by means of press release or other public
statements. We have engaged InvestorCom to assist us in soliciting proxies for the Annual Meeting. We expect the fees payable to InvestorCom
will be approximately $60,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_014"></span>WHERE ARE CNS&#8217; PRINCIPAL EXECUTIVE OFFICES?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal executive offices of CNS Pharmaceuticals
are located at 2100 West Loop South, Suite 900, Houston, TX 77027, and our telephone number is (800)&#160;946-9185.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_015"></span>HOW CAN I OBTAIN ADDITIONAL INFORMATION ABOUT CNS?</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to the informational requirements of
the Securities Exchange Act of 1934, as amended, which requires that we file reports, proxy statements and other information with the
SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding companies, including
CNS Pharmaceuticals, that file electronically with the SEC. The SEC&#8217;s website address is www.sec.gov. In addition, our filings may
be inspected and copied at the public reference facilities of the SEC located at 100 F Street, N.E. Washington, DC 20549.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_016"></span>STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth information, as of October 10, 2025, regarding
beneficial ownership of our common stock by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 48px; text-align: center">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">each of our directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 48px; text-align: center">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">each of our named executive officers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 48px; text-align: center">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">all directors and officers as a group; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 48px; text-align: center">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">each person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beneficial ownership is determined according to the
rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared voting
or investment power of that security and includes warrants and options that are currently exercisable or exercisable within 60 days. Each
director or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated,
we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have sole investment
and voting power with respect to their shares, except where community property laws may apply. Except as otherwise noted below, the address
for each person or entity listed in the table is c/o CNS Pharmaceuticals, Inc., 2100 West Loop South, Suite 900, Houston, TX 77027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 56%"><span style="font-size: 10pt"><b>Name and address of beneficial owner</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Shares Beneficially
    Owned</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Percentage
of Class <sup>(1)</sup></b></span></p></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">John Climaco</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">21 <sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Christopher S. Downs</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">12 <sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Sandra Silberman</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 <sup>(4)</sup> </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Faith Charles</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 <sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Jerzy (George) Gumulka </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">9 <sup>(6)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Jeffry R. Keyes </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6 <sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Bettina Cockroft</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 <sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Amy Mahery</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2 <sup>(9)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><b>Directors and Officers as a group (10 persons)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt"><b>5% or greater stockholders</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Armistice Capital, LLC <sup>(10)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">46,762</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">9.9%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">______________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 9pt">*</span></td>
    <td style="text-align: justify; width: 97%"><span style="font-size: 9pt">Less than 1%.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Based on 574,580 shares of common stock outstanding as of October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(2) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Includes warrants to purchase 10 shares of common stock which are exercisable within 60 days of
    October 10, 2025 and options to purchase 6 shares of common stock which are exercisable within 60 days of October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(3) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Includes warrants to purchase 4 shares of common stock which are exercisable within 60 days of October
    10, 2025 and options to purchase 5 shares of common stock which are exercisable within 60 days of October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(4) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Consists of options to purchase 5 shares of common stock which are exercisable within 60 days of
    October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(5) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Consists of options to purchase 3 shares of common stock which are exercisable within 60 days of
    October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(6) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Includes options to purchase 2 shares of common stock which are exercisable within 60 days of October
    10, 2025 and options to purchase 5 shares of common stock which are exercisable within 60 days of October 10, 2025.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(7) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Consists of options to purchase 6 shares of common stock which are exercisable within 60 days of
    October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(8) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Consists of options to purchase 4 shares of common stock which are exercisable within 60 days of
    October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9pt">(9) </span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Consists of options to purchase 2 shares of common stock which are exercisable within 60 days of
    October 10, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 9pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Based solely on a Schedule 13G filed with the SEC on August 14, 2025
    on behalf of Armistice Capital, LLC and Steven Boyd. Armistice Capital, LLC ("Armistice Capital") is the investment manager
    of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the shares in the table, and pursuant to
    an Investment Management Agreement, Armistice Capital exercises voting and investment power over our securities held by the Master
    Fund and thus may be deemed to beneficially own the securities held by the Master Fund. Mr. Boyd, as the managing member of Armistice
    Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund specifically disclaims beneficial
    ownership of the securities held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment
    Management Agreement with Armistice Capital. The address of the principal business office of Armistice Capital and Mr. Boyd is c/o
    Armistice Capital, LLC 510 Madison Avenue, 7th Floor, New York, New York 10022.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_017"></span>INFORMATION ABOUT DIRECTORS AND EXECUTIVE OFFICERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Directors and Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth the names and ages of all of our directors
and executive officers as of October 10, 2025. Our officers are appointed by, and serve at the pleasure of, the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 35%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 53%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">John M. Climaco</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">56</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Christopher S. Downs</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">47</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Sandra L. Silberman</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">71</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Medical Officer</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Donald Picker</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">80</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Science Officer</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Faith L. Charles</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">63</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director and Chair of the Board of Directors</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Jerzy (George) Gumulka</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">76</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Jeffry R. Keyes </span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">52</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director </span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Bettina Cockroft</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">58</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Amy Mahery</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">48</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Set forth below is biographical
information about each of the individuals named in the tables above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>John M. Climaco, Esq. &#8211;
Chief Executive Officer and Director</i></b>. Mr. Climaco joined CNS in September 2017 as its Chief Executive Officer. Mr. Climaco has
served in leadership roles in a variety of healthcare companies. From April 2015 to June 2017 Mr. Climaco served as the Executive Vice-President
of Perma-Fix Medical S.A where he managed the development of a novel method to produce Technitium-99. Mr. Climaco also served as President
and CEO of Axial Biotech, Inc., a DNA diagnostics company, from January 2003 to January 2013. In the process of taking Axial from inception
to product development to commercialization, Mr. Climaco created strategic partnerships with Medtronic, Johnson &amp; Johnson and Smith
&amp; Nephew. Mr. Climaco currently serves as a director of several public companies including Moleculin Biotech, Inc., a pharmaceutical
company focused on anticancer drug candidates, where he has served since May 2017. Mr. Climaco served on the boards of Digirad, Inc.,
a leading national provider of imaging services, from May 2012 until April 2020, and Birner Dental Management Services, Inc., a provider
of practice management services in the dental industry, since June 2017. Mr. Climaco also served as a director of PDI, Inc., a provider
of outsourced commercial services to pharma companies, in 2015, and InfuSystem Holdings, Inc., the largest supplier of infusion services
to oncologists in the U.S., from April 2012 to April 2014. Mr. Climaco obtained his Juris Doctorate Degree from the University of California
Hastings College of Law in San Francisco, CA in January 2000 and a Bachelor of Philosophy from Middlebury College in Middlebury, VT, in
May 1991. Mr. Climaco is active with the State Bar of Utah. We believe Mr. Climaco&#8217;s history with our company, coupled with his
vast experience with development stage companies and his legal background provides him with the qualifications to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Christopher S. Downs, CPA
&#8211; Chief Financial Officer. </i></b>Mr. Downs has served as our chief financial officer since the closing of our initial public offering
in November 2019 (the &#8220;IPO&#8221;). From March 2018 until September 2019, Mr. Downs served as vice president of finance and treasurer
of Innovative Aftermarket Systems, L.P., a privately held provider of finance and insurance solutions. Mr. Downs served as director of
finance (from June 2011 to September 2013), vice president and treasurer (October 2013 to August 2016), executive vice president and interim
chief financial officer (August 2016 to May 2017), and executive vice president, interim chief financial officer and member of the office
of the president (May 2017 to March 2018) for InfuSystem Holdings, Inc., a supplier of infusion services to oncologists in the United
States. Mr. Downs spent 10 years in investment banking with various firms including Citigroup. Mr. Downs served as a director of EBET,
Inc., a technology company developing and operating platforms focused on esports and competitive gaming, from March 2021 to July 2024.
Mr. Downs is a graduate of the United States Military Academy at West Point where he earned his Bachelor of Science. Mr. Downs earned
his MBA at Columbia Business School and his Master of Science in Accounting at the University of Houston-Clear Lake. Mr. Downs is a Certified
Public Accountant in Utah and Texas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sandra L. Silberman,
MD PhD &#8211; Chief Medical Officer</i></b>. Dr. Silberman joined CNS in December 2017. Dr. Silberman served as chief medical officer
for new products of Moleculin Biotech, Inc. from November 2017 to December 2024 on a part-time basis. Dr. Silberman advanced several original,
proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including BristolMyers Squibb,
AstraZeneca, Imclone and Roche. Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins
University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University
Medical College, and then completed both a clinical fellowship in Hematology/Oncology as well as a research fellowship in tumor immunology
at the Brigham &amp; Women&#8217;s Hospital and the Dana Farber Cancer Institute in Boston, MA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Donald Picker, PhD -
Chief Science Officer</i></b>. Dr. Picker has served as our part-time chief science officer since June 2019. Dr. Picker has served as
the chief scientific officer of Moleculin Biotech, Inc. since August 2017 after serving as its chief operating officer from July 2015
until August 2017 and as its president from January 2016 to August 2017. In 2007, Dr. Picker became the chief executive officer of IntertechBio
Corp. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy
Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006.
From 2017 to 2018, Dr. Picker served on our board of directors. Dr. Picker received his B.S. degree from Brooklyn Polytechnic University
and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only 25% of his work time to us and provides services as needed
to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Faith L. Charles, JD
&#8211; Director and Chair of the Board of Directors</i></b>. Ms. Charles joined our board of directors on December 30, 2022 and currently
serves as chair of the board of directors. Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson
Hine, LLP, since 2010. She leads Thompson Hine&#8217;s Life Sciences practice and co-heads the securities practice, advising public and
emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing
transactions, mergers and acquisitions, licensing transactions and strategic collaborations. She serves as outside counsel to a myriad
of life sciences companies and is known in the industry as an astute business advisor, providing valuable insights into capital markets,
corporate governance and strategic development. From 2025 to present, Ms. Charles has served on the board of directors and as a member
of the compensation committee and chair of the nominating and governance committee of Abeona Therapeutics, Inc., a publicly traded biotechnology
company. From 2021 to present, Ms. Charles has served on the board of directors and as a member of the audit committee and as a member
of the compensation committee of Avenue Therapeutics, Inc., a publicly traded biotechnology company. From 2018 until October 2021, Ms.
Charles served on the board of directors and as a member of the audit committee and chair of the compensation committee of Entera Bio,
a publicly traded biotechnology company. She also serves on the Board of Directors of several private life science companies. Ms. Charles
founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She currently serves on the national board of
Women in Bio. Ms. Charles is also a member of the board of Red Door Community (formerly Gilda&#8217;s Club New York City). She has been
recognized as a Life Sciences Star by Euromoney&#8217;s LMG Life Sciences, has been named a BTI Client Service All-Star, and was named
by Crain&#8217;s New York Business to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D. degree from The George Washington
University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio&#8217;s
Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business. Ms. Charles qualifications
to serve on our Board include her leadership skills and her vast legal experience representing companies in the biotech and pharmaceutical
field.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jerzy (George) Gumulka,
PhD &#8211; Director</i></b>. Dr. Gumulka joined our board of directors on November 8, 2017. Dr. Gumulka has been retired since 2016.
From 2001 until his retirement, he served as a Global Technology Manager ASC, a Technology Manager, Special Projects/New Technology Platforms,
Kraton Polymers US LLC, and a Technical Director of Kraton Polymers do Brasil. Prior to his employment at Shell Chemical Company and Kraton
Polymers US LLC, Dr. Gumulka worked at BioSpectrum, Inc. (aka IML) and was involved in the development and application of Human Immune
Interferon (INF-&#947;) and Interleukin-2 in the HIV-focused clinical studies and animal models. Dr. Gumulka co-authored patents on the
production and purification of INF-&#947; and Interleukin-2, and in the field of analytical chemistry, environmental and polymer science.
Dr. Gumulka is the recipient of the 2011 Presidential Green Chemistry Challenge Award. Dr. Gumulka served on the Board of Directors of
Moleculin LLC from 2010 through 2016. Dr. Gumulka received a Ph.D. from the University of Warsaw, Warsaw, Poland. We believe Dr. Gumulka&#8217;s
technical knowledge and experience in the field of biochemistry coupled with his vast experience in corporate leadership provide him with
the qualifications to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Jeffry R. Keyes &#8211;
Director</i></b>. Mr. Keyes joined our board on June 25, 2018. Mr. Keyes is currently the Chief Financial Officer of Quantum-Si Incorporated,
a publicly-held proteomics company, a role that he has held since May 2023. From August 2022 to May 2023, Mr. Keyes was the Chief Financial
Officer of Spinal Elements, Inc., a private equity backed medical device company. From April 2018 to August 2022, Mr. Keyes was the Chief
Financial Officer of Custopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals. From September
2012 to April 2018, Mr. Keyes was the Chief Financial Officer and Corporate Secretary of Digirad Corporation, a publicly traded healthcare
services and medical device company. From August 2011 until September 2012, Mr. Keyes was Corporate Controller of Sapphire Energy, Inc.,
a venture capital backed start-up renewable energy company. From April 2011 to August 2011, Mr. Keyes was the Corporate Controller of
Advanced BioHealing, Inc., a venture backed provider of regenerative medicine solutions, until its sale to Shire, PLC in August 2011.
Prior to April 2011 Mr. Keyes held a variety of leadership roles in healthcare and medical device companies in finance, accounting, and
M&amp;A support, and he started his career in public accounting. Mr. Keyes earned a B.A. degree in accounting from Western Washington
University and is a certified public accountant licensed by the Washington State Board of Accountancy. Mr. Keyes is considered a financial
expert under relevant rules of the SEC, the NYSE and Nasdaq. We believe Mr. Keyes&#8217; financial knowledge and experience, which qualify
him as an Audit Committee Financial Expert, coupled with his vast experience in corporate leadership provides him with the qualifications
to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Bettina M. Cockroft, MD
&#8211; Director.</i></b> Dr. Cockroft joined our board on May 3, 2023. Since January 2025, Dr. Cockroft serves as Chief Medical Officer
of Cilcare Inc., a biotech company developing therapeutics for hearing disorders. From September 2019 to May 2023, Dr. Cockroft was Senior
Vice President and Chief Medical Officer of Sangamo Therapeutics, Inc., a publicly-held biotechnology company, where she oversaw clinical
development activities and operations. She has over 20 years of experience in the biopharmaceutical industry and has worked across multiple
therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at
Cytokinetics, Inc., a publicly-held biopharmaceutical company, where she was responsible for clinical development of fast skeletal muscle
troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. She served as Vice President, Clinical
Research, Neurology, at Cytokinetics from August 2017 to September 2019. From October 2016 to July 2017, Dr. Cockroft served as a pharmaceutical
executive consultant, and before that, from September 2013 to September 2016, she served as Chief Medical Officer of Auris Medical AG,
a biopharmaceutical company, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also
held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career. Dr.
Cockroft has served as a member of the board of directors of Annexon, Inc. since January 2022 including serving as a member of the audit
committee and the science and technology committee. Dr. Cockroft received a M.B.A. from MIT Sloan School of Management and a M.D. from
the University of Genova. We believe Dr. Cockroft&#8217;s extensive experience in the biotechnology field provides her with the qualifications
to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Amy Mahery &#8211; Director</i></b>.
Ms. Mahery joined our board on February 1, 2024. Since February 2025, Ms. Mahery has served as Chief Marketing Officer of Moderna, Inc.
From August 2022 to December 2024, Ms. Mahery served as Chief Commercial Officer of Roivant Sciences.. From April 2021 until July 2022,
Ms. Mahery served as Senior Vice President, Global Franchise Head &#8211; Neurology &amp; Immunology for EMD Serono, Inc. and from 2019
until 2021 Ms. Mahery served as Senior Vice President, Head &#8211; Global Market Access and Pricing for EMD Serono, Inc. Ms. Mahery holds
a B.S. degree in Neuroscience from Trinity College-Hartford. We believe Ms. Mahery&#8217;s extensive experience in the biopharmaceuticals
industry provides her with the qualifications to serve as a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No director is related to any other director or executive
officer of our company or our subsidiaries, and, there are no arrangements or understandings between a director and any other person pursuant
to which such person was elected as director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_018"></span>GOVERNANCE OF THE COMPANY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors oversees the business affairs
of CNS Pharmaceuticals and monitors the performance of management. Pursuant to our Amended and Restated Bylaws, the Board of Directors
shall consist of no less than one director. Members of the Board of Directors discussed various business matters informally on numerous
occasions throughout the year 2024. During 2024 the Board held 23 meetings. In addition to meetings of the full Board of Directors, our
Board has established an Audit Committee, Compensation Committee, Pricing Committee and Nominating and Corporate Governance Committee.
During 2024, these Board committees held an additional 19 meetings during the year. Specifically, the breakdown of the committee meetings
for 2024 are as follows: 12 for the Audit Committee, 4 for the Compensation Committee, 1 for the Pricing Committee and 2 for the Nominating
and Corporate Governance Committee. We believe that such interaction between fellow Board members and with management provided proper
oversight of the Company. Each incumbent director attended at least 75% of the total number of meetings of the Board of Directors and
committee meetings of which such director was a member (held during the period for which such director was in office).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board is currently comprised of six members,
five of whom are independent directors per the NASDAQ Stock Market rules. To date, we believe the size of our Board has been sufficient
for a company of our size. We further believe that the six directors nominated for election are sufficient for the Company. No current
director or executive officer has any family relationship with any other executive officer, director, or director nominee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The rules of the Nasdaq Stock Market, or the Nasdaq
Rules, require a majority of a listed company&#8217;s board of directors to be composed of independent directors. In addition, the Nasdaq
Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and governance
committees be independent. Under the Nasdaq Rules, a director will only qualify as an independent director if, in the opinion of our Board
of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out
the responsibilities of a director. The Nasdaq Rules also require that audit committee members satisfy independence criteria set forth
in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent for purposes
of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit
committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory
fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.
In considering the independence of compensation committee members, the Nasdaq Rules require that our board of directors must consider
additional factors relevant to the duties of a compensation committee member, including the source of any compensation we pay to the director
and any affiliations with our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our board of directors undertook a review of the composition
of our board of directors and its committees and the independence of each director. Based upon information requested from and provided
by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined
that each of our directors, with the exception of Mr. Climaco, are independent as defined under the Nasdaq Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The independent directors meet as often as necessary
to fulfill their responsibilities, including meeting at least four times annually in executive session without the presence of non-independent
directors and management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Board Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We established a Nominating and Corporate Governance
Committee, an Audit Committee a Pricing Committee and a Compensation Committee. Our Board of Directors has adopted and approved a charter
for each of these standing committees. The charters, which include the functions and responsibilities of each of the committees, can be
found in the &#8220;Investors - Corporate Governance&#8221; section on our web site at www.cnspharma.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Audit Committee</i>. The members of the Audit Committee
are Mr. Keyes (Chair), Ms. Charles, and Ms. Mahery. Each member of the Audit Committee is independent as defined by the Nasdaq Rules.
In addition, each member of the Audit Committee satisfies the additional requirements of the SEC and Nasdaq Rules for audit committee
membership, including the additional independence requirements and the financial literacy requirements. The Board has determined that
at least one member of the Audit Committee, Mr. Keyes, is an &#8220;audit committee financial expert&#8221; as defined in the SEC&#8217;s
rules and regulations. The primary purpose of the Audit Committee is to oversee the quality and integrity of our accounting and financial
reporting processes and the audit of our financial statements. The Audit Committee is responsible for selecting, compensating, overseeing
and terminating the selection of our independent registered public accounting firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Nominating and Corporate Governance Committee.</i>
The members of the Nominating and Corporate Governance Committee are Dr. Cockroft (Chair) and Ms. Charles. Each member of the Nominating
and Corporate Governance Committee is independent as defined by Nasdaq Rules. The primary functions and responsibilities of the Nominating
and Corporate Governance Committee are to: (a) determine the qualifications, qualities, skills, and other expertise required to be a director;
(b) identify and screen individuals qualified to become members of the Board; (c) make recommendations to the Board regarding the selection
and approval of the nominees for director; and (d) review and assess the adequacy of our corporate governance policies and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Compensation Committee</i>. The members of the
Compensation Committee are Ms. Mahery (Chair), Dr. Gumulka, and Dr. Cockroft. Each member of the Compensation Committee is independent
as defined by Nasdaq Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee is responsible for, among
other things, reviewing and making recommendations to the Board of Directors with respect to the annual compensation for our Chief Executive
Officer. The Compensation Committee also is responsible for reviewing and making recommendations to the Board of Directors regarding the
annual compensation and benefits for our other executive officers. The Compensation Committee also, among other things, reviews compensation
of the Board, reviews and makes recommendations on all new executive compensation programs that are proposed for adoption and administers
the Company&#8217;s equity incentive plans. The Compensation Committee is responsible for reviewing director compensation for service
on the Board and Board committees at least once a year and to recommend any changes to the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Chief Executive Officer reviews the performance
of our other executive officers (other than himself) and, based on that review, our Chief Executive Officer makes recommendations to the
Compensation Committee about the compensation of executive officers (other than himself). Our Chief Executive Officer does not participate
in any deliberations or approvals by the Board or the Compensation Committee with respect to his own compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Board Member Attendance at Annual Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have a formal policy regarding Board attendance
at our annual meetings, however, all of our directors are invited to the annual meeting. Four of our directors attended our 2024 annual
meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Board Leadership Structure and Role in Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2022, John Climaco served as both our Chief
Executive Officer and Chairperson of the Board. In December 2022, Ms. Charles joined our Board of Directors and assumed the position of
Chairperson. Our Board of Directors has no policy with regard to the separation of the offices of Chairperson of the Board and Chief Executive
Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for managing risks,
including cybersecurity risks, in our business, and develops processes to manage and monitor risks. The Board views its role as one of
oversight and reviews and assesses these risks regularly. The Board focuses on understanding management&#8217;s risk management systems,
the effectiveness of those systems, and the way in which management proactively manages risks. In addition, the Board utilizes the Nominating
and Corporate Governance Committee, the Audit Committee and the Compensation Committee to manage risks that arise under each committee&#8217;s
area of focus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 40pt 0 0; text-align: justify"><b>Nomination of Director Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 40pt 0 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We receive suggestions for potential director nominees
from many sources, including members of the Board, advisors, and stockholders. Any such nominations, together with appropriate biographical
information, should be submitted to the Chairperson of the Nominating and Corporate Governance Committee in the manner discussed below.
Any candidates submitted by a stockholder or stockholder group are reviewed and considered in the same manner as all other candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Qualifications for consideration as a Board nominee
may vary according to the particular areas of expertise being sought as a complement to the existing board composition. However, minimum
qualifications include high level leadership experience in business activities, breadth of knowledge about issues affecting the Company,
experience on other boards of directors, preferably public company boards, and time available for meetings and consultation on Company
matters. Our Nominating and Corporate Governance Committee does not have a formal policy with regard to the consideration of diversity
in identifying director candidates, but seeks a diverse group of candidates who possess the background, skills and expertise to make a
significant contribution to the Board, to the Company and our stockholders. Candidates whose evaluations are favorable are recommended
by our Nominating and Corporate Governance Committee to the full Board for consideration. The full Board selects and recommends candidates
for nomination as directors for stockholders to consider and vote upon at the annual meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A stockholder wishing to nominate a candidate for
election to our Board of Directors at any annual meeting at which the Board of Directors has determined that one or more directors will
be elected must submit a written notice of his or her nomination of a candidate to the Chairperson of the Nominating and Corporate Governance
Committee (c/o&#160;the Corporate Secretary), providing the candidates name, biographical data and other relevant information together
with a consent from the nominee. Pursuant to our Amended and Restated Bylaws, the submission must be received at our principal executive
offices 120 days prior to the anniversary date of the mailing date of our previous year&#8217;s proxy statement so as to permit the Board
of Directors time to evaluate the qualifications of the nominee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, 2023 and 2024, we employed and paid executive
search firms to assist us in locating qualified candidates for director positions as the Board sought to expand and diversify its membership.
Ms. Charles, Dr. Cockroft and Ms. Mahery were identified through the search firms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to satisfying the foregoing requirements
under our Amended and Restated Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support
of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange
Act no later than September 18, 2026 (i.e., the date that is 60 days prior to the anniversary date of this annual meeting of stockholders).
The requirements under the universal proxy rules are in addition to the applicable procedural requirements under our Amended and Restated
Bylaws described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stockholder Communications with Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Persons wishing to write to our Board of Directors,
or to a specified director or committee of the Board, should send correspondence to the Corporate Secretary at 2100 West Loop South, Suite
900, Houston, TX 77027. Electronic submissions of stockholder correspondence will not be accepted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporate Secretary will forward to the directors
all communications that, in his or her judgment, are appropriate for consideration by the directors. Examples of communications that would
not be appropriate for consideration by the directors include commercial solicitations and matters not relevant to the stockholders, to
the functioning of the Board or to the affairs of CNS. Any correspondence received that is addressed generically to the Board of Directors
will be forwarded to the Chairperson of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Insider Trading Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_901_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20251117__20251117_zIMst4kVBBP8"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleantrue" id="Fact000012" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Our insider trading policy, which is included
in our code of ethics, prohibits our directors, executive officers, and employees from purchasing or selling our securities while being
aware of material, non-public information about the Company as well as disclosing such information to others who may trade in securities
of the Company.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Anti-Hedging Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our policies prohibit directors, officers and other
employees from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds),
or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our
equity securities without our prior approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a written code of ethics that
applies to our directors, principal executive officer, principal financial officer, principal accounting officer or controller and any
persons performing similar functions. The code of ethics is on the &#8220;Investors - Governance - Governance Documents&#8221; section
of our website at www.cnspharma.com. We intend to disclose any future amendments to, or waivers from, the code of ethics within four business
days of the waiver or amendment through a website posting or by filing a Current Report on Form 8-K with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Delinquent Section 16(a) Reports</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 16(a) of the Exchange Act requires that our
executive officers and directors, and persons who own more than 10% of our common stock, file reports of ownership and changes of ownership
with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulation to furnish us with copies of all
Section 16(a) forms they file.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEC regulations require us to identify anyone who
filed a required report late during the most recent fiscal year. Based solely on our review of copies of such forms that we have received,
or written representations from reporting persons, we believe that during 2024, all executive officers, directors and greater than 10%
stockholders complied with all applicable SEC filing requirements, except as follows: Messrs. Climaco, Downs, Carl Evans (a former director),
Dr. Gumulka and Ms. Mahery each filed one Form 4 reporting one transaction one day late on February 6, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_019"></span>COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Officer Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our named executive officers for the years ended December
31, 2024 and December 31, 2023, which consist of our principal executive officer and our two other most highly compensated executive officers,
are: (i) John Climaco, our chairman and chief executive officer; (ii) Chris Downs, our chief financial officer; and (ii) Sandra Silberman,
our chief medical officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b><span id="a_020"></span>Summary Compensation Table &#8211;
2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 37%"><span style="font-size: 10pt"><b>Name and Principal Position</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Salary<br/>
($)</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Stock Awards<br/>
($)(1)</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Option</b><br/>
<b>awards</b><br/>
<b>($) (1)</b></span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 11%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Nonequity incentive plan compensation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Total</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>($)</b></span></p></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">John Climaco, Chief Executive Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">525,000</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">292,817</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">285,863</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1,103,680</span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">525,000</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">20,688</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">18,022</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">60,638</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">624,348</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Christopher Downs, Chief Financial Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">340,000</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">146,410</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">134,640</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">621,050</span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">340,000</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,344</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">9,011</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">42,160</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">401,515</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Sandra Silberman, Chief Medical Officer</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">200,000</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">73,205</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">88,436</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">361,641</span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">200,000</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">4,784</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">4,168</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">61,200</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">270,152</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Represents the full grant date fair value of the
awards calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized
by the named executive officer. Option awards for the 2024 calendar year were granted in March 2025 and option awards for 2023 were granted
in April 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Narrative Disclosure to Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review compensation annually for all employees,
including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation
for comparable positions in the market, the individual executive&#8217;s performance as compared to our expectations and objectives, our
desire to motivate our employees to achieve short and long-term results that are in the best interests of our stockholders and a long-term
commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus
or long-term incentives. Our Compensation Committee typically reviews and discusses management&#8217;s proposed compensation with the
Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, the
Compensation Committee then determines the compensation for each executive officer. Our Compensation Committee, without members of management
present, discusses and ultimately approves the compensation of our executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Annual Base Salary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For 2024, the base salaries for Mr. Climaco, Mr. Downs,
and Dr. Silberman did not change from the prior year and were $525,000, $340,000, and $200,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Annual Bonus and Non-Equity Incentive Plan Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to motivate and reward our executives for
achievements relative to our corporate goals and objectives for each fiscal year. For the 2024 compensation year, the target bonus for
Mr. Climaco, Mr. Downs and Dr. Silberman were 50%, 40%, and 40%, respectively, of their base salary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The actual performance-based annual bonus paid is
calculated by multiplying the executive&#8217;s annual base salary, target bonus percentage, the percentage attainment of the corporate
goals established by the Board for such year. However, the Compensation Committee is not required to calculate bonuses in this manner
and retains discretion in the amounts it awards and the factors it takes into consideration in determining bonus amounts. At the end of
the year, the Compensation Committee reviews our performance against our goals and objectives and approves the extent to which we achieved
each of our corporate goals and objectives, and, for each named executive officer, the amount of the bonus awarded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For 2024, bonuses were awarded based on our achievement
of specified corporate goals, including our ability to maintain sufficient funding, certain intellectual property development goals, and
preparatory activities for submission of a New Drug Application for Berubicin. Based on the level of achievement, our Compensation Committee
awarded Mr. Climaco, Mr. Downs and Dr. Silberman 99%, 99% and 99.5% of their potential bonuses for 2024. These actual bonus amounts are
reflected in the &#8220;Non-Equity Incentive Plans&#8221; column of the Summary Compensation Table above.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For 2025, bonuses will be awarded at the discretion
of the board of directors based on our achievement of specified corporate goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Long-Term Incentives</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each year our Compensation Committee provides for
equity grants to each of our named executive officers to provide for long-term performance incentive. On March 11, 2025, the Compensation
Committee recommended, and the Board approved such recommendation, equity grants for service in 2024 from the Stock Plan, subject to stockholder
approval to increase the number of shares underlying the Stock Plan, for a total of options to purchase 17,082 shares of common stock
at an exercise price of $30.36 that vest over 2 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recoupment Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90C_eecd--RecoveryOfErrCompDisclosureLineItems_c20251117__20251117_zafDqIkFobW4">We adopted the CNS Pharmaceuticals, Inc. Dodd-Frank
Restatement Recoupment&#160;Policy effective as of October 2, 2023. In the event that we are required to prepare a financial restatement,
the Committee will recoup all erroneously awarded incentive-based compensation calculated on a pre-tax basis received after October 2,
2023, by a person (i) after beginning service as an executive officer, (ii) who served as an executive officer at any time during the
performance period for that incentive-based compensation, and (iii) during the three completed fiscal years immediately preceding the
date that the Company is required to prepare a Restatement, and any transition period (that results from a change in the Company&#8217;s
fiscal year) of less than nine months within or immediately following those three completed fiscal years. A &#8220;clawback&#8221; or&#160;recoupment&#160;policy
in our executive compensation program contributes to creating and maintaining a culture that emphasizes integrity and accountability and
reinforces the performance-based principles underlying our executive compensation program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Granting of Certain Equity Awards Close in Time
to the Release of Material Nonpublic Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90A_eecd--AwardTmgMnpiDiscTextBlock_c20251117__20251117_zIb7ghV35Ga2"><ix:nonNumeric contextRef="AsOf2025-11-17" escape="true" id="Fact000014" name="ecd:AwardTmgMnpiDiscTextBlock">We do <span id="xdx_908_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20251117__20251117_zFNJUWyRfjO"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleantrue" id="Fact000015" name="ecd:AwardTmgMnpiCnsdrdFlag">no</ix:nonNumeric></span>t grant equity awards in anticipation of the
release of material nonpublic information, and do not time the public release of such information based on award grant dates.</ix:nonNumeric></span> <span id="xdx_909_eecd--MnpiDiscTimedForCompValFlag_dbF_c20251117__20251117_zAmoNKiwdlQd"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000016" name="ecd:MnpiDiscTimedForCompValFlag">During the
last completed fiscal year, we have not made awards to any named executive officer during the period beginning four business days before
and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report
on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive
compensation.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>John Climaco</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 1, 2017, we entered into an employment
agreement with John Climaco pursuant to which Mr. Climaco agreed to serve as our Chief Executive Officer commencing on such date for an
initial term of three years. On September 1, 2020, we entered into an amendment to the employment agreement. The amendment extends the
term of employment under the employment agreement for additional twelve-month periods, unless and until either the Company or Mr. Climaco
provides written notice to the other party not less than sixty days before such anniversary date that such party is electing not to extend
the term. If the Company provides notice of its election not to extend the term, Mr. Climaco may terminate his employment at any time
prior to the expiration of the term by giving written notice to the Company at least thirty days prior to the effective date of termination,
and upon the earlier of such effective date of termination or the expiration of the term, Mr. Climaco shall be entitled to receive the
same severance benefits as are provided upon a termination of employment by the Company without cause. Pursuant to the amendment, the
severance benefits shall be twelve months of Mr. Climaco&#8217;s base salary. Such severance payment shall be made in a single lump sum
sixty days following the termination, provided that Mr. Climaco has executed and delivered to the Company, and has not revoked a general
release of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Other Executive Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2019, we entered into employment letters
with Drs. Silberman and Picker. Dr. Silberman agreed to commit 50% of her time to our matters and Dr. Picker agreed to commit 25% of his
time to our matters. In January 2025, Dr. Silberman agreed to commit 100% of her time to our matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Outstanding Equity Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth certain information
concerning our outstanding options for our named executive officers on December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b><span id="a_021"></span>Outstanding Equity Awards At
Fiscal Year-End &#8212;2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td colspan="11" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 9pt"><b>Option
    Awards</b></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Stock
    Awards (2)</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt"><b>Name</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 9pt"><b>Grant Date of Equity Award</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Number of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Securities</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Underlying</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Unexercised</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Options</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>(#)</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Exercisable (1)</b></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Number of </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Securities </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Underlying </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Unexercised </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Options (#) </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Unexercisable
    (1)</b></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Option</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Exercise<br/>
    Price</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>($)</b></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 9pt"><b>Option</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 9pt"><b>Expiration
    Date</b></span></p></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Number of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>shares or</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>units of stock</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>that have</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>not vested (#)</b></span></p></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>Market value</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>of shares of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>units of stock</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>that have</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 9pt"><b>not vested ($)
    (3)</b></span></p></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="width: 16%"><span style="font-size: 9pt">John Climaco</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: center"><span style="font-size: 9pt">4/7/2024</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 9pt">2</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 9pt">7,758</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: center"><span style="font-size: 9pt">4/27/2034</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 9pt">2</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 9pt">144</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/29/2023</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">29,880</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/27/2033</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">4/28/2022</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2021</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">3,024,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2031</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">6/28/2019</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1,800,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">6/28/2029</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-size: 9pt">Christopher Downs</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">4/7/2024</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">7,758</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">4/27/2034</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">72</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/29/2023</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">29,880</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/27/2033</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">4/28/2022</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2021</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">3,024,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2031</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">11/13/2019</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">3,600,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">11/13/2029</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">Sandra Silberman</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">4/7/2024</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">7,758</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">4/27/2034</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">72</span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/29/2023</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">29,880</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">3/27/2033</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">4/28/2022</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2021</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">3,024,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">2/5/2031</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">6/28/2019</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1,800,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">6/28/2029</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">12/22/2017</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">1</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">40,500</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">12/22/2027</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The shares underlying the options vest in equal
annual installments over a four-year period (i.e., one-quarter of each grant vests on the first, second, third and fourth anniversary
of the grant date).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Consists of restricted stock unit awards that
vest as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; text-indent: 0.15pt"><span style="font-size: 10pt">25% of the RSU grant will vest in four (4) equal annual installments over 4 years, provided officer is serving in such position on each vesting date;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; text-indent: 0.15pt"><span style="font-size: 10pt">25% of the RSU grant will vest if within 24 months from grant the average of the closing price of the Company&#8217;s common stock over a ten trading day period exceeds $1,800,000.00 (subject to pro rata adjustment for stock splits or similar events);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; text-indent: 0.15pt"><span style="font-size: 10pt">25% of the RSU grant will vest if within 36 months from grant the average of the closing price of the Company&#8217;s common stock over a ten trading day period exceeds $3,600,000.00 (subject to pro rata adjustment for stock splits or similar events);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; text-indent: 0.15pt"><span style="font-size: 10pt">25% of the RSU grant will vest if within 24 months from issuance the Company achieves &#8220;Positive Interim, Clinical Data&#8221; as defined by the Board of Directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(3) Based on the closing price of our common stock on December 31, 2024
of $72.00.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_022"></span>Pay Versus Performance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
section provides disclosure about the relationship between executive compensation actually paid to our principal executive officer (&#8220;PEO&#8221;)
and non-PEO Named Executive Officers (&#8220;NEOs&#8221;) and certain financial performance measures of the Company for the fiscal years
listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Exchange Act (the &#8220;Pay
Versus Performance Rules&#8221;) and does not necessarily reflect how the Compensation Committee evaluates compensation decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fiscal Year <sup>(1)</sup></b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Summary compensation table total for PEO <sup>(2)</sup></b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Compensation actually paid to PEO <sup>(3) (4)</sup></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Average summary compensation table total for non-PEO named executive officers <sup>(5)</sup></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Average compensation actually paid to non-PEO named executive officers <sup>(6)</sup></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Value of Initial Fixed $100 Investment Based on Total shareholder Return <sup>(7)</sup></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Net Loss (in thousands) <sup>(8)</sup></b></span></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top; width: 13%"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">1,103,680</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">677,722</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">982,691</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">454,522</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">0.19</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-size: 10pt">(14,858</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr>
    <td style="vertical-align: top; background-color: white"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: top; background-color: #EEEEEE"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: #EEEEEE; text-align: right"><span style="font-size: 10pt">624,348</span></td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: white; text-align: right"><span style="font-size: 10pt">846,871</span></td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: white; text-align: right"><span style="font-size: 10pt">671,667</span></td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: white; text-align: right"><span style="font-size: 10pt">1,196,301</span></td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: white; text-align: right"><span style="font-size: 10pt">52.92</span></td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; background-color: white; text-align: right"><span style="font-size: 10pt">(18,851</span></td>
    <td style="vertical-align: bottom; background-color: white"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">2022</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">827,928</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,578,131</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">762,530</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1,881,416</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">11.40</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(15,274</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) The following table lists the PEO and non-PEO&#160;NEOs for each of
fiscal years 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><i></i></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center; width: 17%">Fiscal Year</td>
    <td style="padding-bottom: 1pt; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center; width: 28%">PEO</td>
    <td style="padding-bottom: 1pt; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center; width: 51%">Non-PEO NEOs</td></tr>
  <tr style="vertical-align: bottom; background-color: #E8E8E8">
    <td style="text-align: center">2024</td>
    <td>&#160;</td>
    <td style="text-align: center">John M. Climaco</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">Christopher Downs and Sandra Silberman</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">2023</td>
    <td>&#160;</td>
    <td style="text-align: center">John M. Climaco</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">Christopher Downs and Sandra Silberman</td></tr>
  <tr style="vertical-align: bottom; background-color: #E8E8E8">
    <td style="text-align: center">2022</td>
    <td>&#160;</td>
    <td style="text-align: center">John M. Climaco</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">Christopher Downs and Sandra Silberman</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(2) The dollar amounts reported in column
(b) are the amounts of total compensation reported for our CEOs for each corresponding year in the &#8220;Total&#8221; column of the
Summary Executive Compensation Table. 'Refer to &#8220;Executive and Director Compensation&#8212;Summary Executive Compensation
Table&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(3) The dollar amounts reported represent the
amount of &#8220;compensation actually paid,&#8221; as calculated in accordance with the Pay Versus Performance Rules. These dollar amounts
do not reflect the actual amounts of compensation earned by or paid to our PEOs during the applicable year. For purposes of calculating
&#8220;compensation actually paid,&#8221; the fair value of equity awards is calculated in accordance with FASB ASC Topic 718 using the
same assumption methodologies used to calculate the grant date fair value of awards for purposes of the
Summary Compensation Table (refer to the Summary Compensation Table for additional information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(4) The following table shows the amounts deducted from and added to the Summary Compensation Table total to calculate &#8220;compensation actually paid&#8221; to our PEOs in accordance with the Pay Versus Performance Rules:</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reported Summary Compensation Table Total for PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reported Value of Equity Awards (A)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Award Adjustments (B)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 19%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">1,103,680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(292,817</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(133,141</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">677,722</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">624,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(38,710</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">261,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">846,871</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">827,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,178</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">764,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,578,131</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(A) The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Executive Compensation Table for the applicable year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(B) The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Equity Award Adjustments</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 16%; text-align: center">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(123,551</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,635</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,287</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(133,141</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">163,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">74,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">261,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(244,227</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,635</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">738,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">672,511</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(5) The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#8217;s Non-PEO NEOs as a group in the &#8220;Total&#8221; column of the Summary Executive Compensation Table in each applicable year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(6) The dollar amounts reported in column
(e) represent the average amount of &#8220;compensation actually paid&#8221; to the Non-PEO NEOs as a group, as computed in
accordance with the Pay Versus Performance Rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year.
In accordance with the Pay Versus Performance Rules, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the compensation actually paid, using the same methodology
described above in Note (4)(B):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Reported Summary Compensation Table Total for Non-PEO NEOs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Reported Value of Equity Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: normal; text-align: center">Average Equity Award Adjustments <span style="font: normal 700 10pt Times New Roman, Times, Serif"><sup>(a)</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Compensation Actually Paid to Non-PEO NEOs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 19%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">982,691</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(219,615</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(308,554</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">454,522</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">671,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(28,307</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">552,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,196,301</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">762,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,530</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,125,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,881,416</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(a) The amounts deducted or added in calculating the total average equity award adjustments are as follows:</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Average Equity Award Adjustments</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 16%; text-align: center">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(268,416</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(49,535</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(308,554</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">348,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">138,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">552,941</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">414,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(964,255</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">161,345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,514,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,125,416</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(7) Assumes $100 invested in our common shares on December 31, 2021, and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period, and reinvestment of all dividends. No cash dividends were paid in 2022, 2023 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(8) The dollar amounts reported represent the
amount of net loss reflected in our consolidated audited financial statements for the applicable year.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Relationship Between &#8220;Compensation Actually Paid&#8221; and Performance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generally seek to incentivize long-term performance
and therefore do not specifically align our performance measures with &#8220;compensation actually paid&#8221; (as computed in accordance
with Pay Versus Performance Rules) for a particular year. In accordance with the Pay Versus Performance Rules, we are providing the following
descriptions of the relationships between information presented in the Pay Versus Performance table.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Compensation Actually Paid and Net Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our company has not historically looked to net
loss as a performance measure for our executive compensation program. Our net loss was $15.3 million in 2022, $18.9 million in 2023 and
$14.9 million in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the total compensation
earned by our non-employee directors in 2024 (Mr. Climaco did not earn additional compensation during 2024 for his services on the Board,
and his compensation is fully reflected in the &#8220;&#8212;Summary Compensation Table&#8221; above):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 25%; text-align: justify"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Fees earned or paid in cash ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Option Awards ($) (1)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Total ($)</b></span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Faith L. Charles</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">78,882</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">78,882</span></td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Jeff Keyes</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">59,750</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">59,750</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Bettina Cockroft</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">52,875</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">52,875</span></td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Jerzy Gumulka</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">50,925</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">50,925</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Carl Evans</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">15,290</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">15,290</span></td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Andy Andraczke</span></td>
    <td style="border-right: black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">11,375</span></td>
    <td style="border-right: black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">11,375</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Amy Mahery</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">46,828</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">46,828</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) As of December 31, 2024, the aggregate number
of shares outstanding under all options to purchase our common stock and stock awards held by our non-employee directors were: Dr. Gumulka
&#8211; 1 shares underlying options and 1 shares underlying restricted stock units; Mr. Keyes &#8211; 1 shares underlying options and
7 shares underlying restricted stock units; Ms. Charles &#8211; 1 shares underlying options and 1 shares underlying restricted stock units;
Ms. Cockroft &#8211; 1 shares underlying options and 1 shares underlying restricted stock units; and Ms. Mahery &#8211; 1 shares underlying
options and 1 shares underlying restricted stock units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2024, our compensation committee recommended
to our Board and our Board approved the following policy to become effective April 1, 2024 for compensating non-employee members of the
Board. Each independent director shall receive annual cash compensation of $40,000. In addition, the chairperson of the Audit Committee,
Compensation Committee and Nominating and Governance Committee shall receive an annual compensation of $15,000, $12,000 and $8,000, respectively;
the other members of such committees shall receive an annual compensation of $7,500, $6,000 and $4,000, respectively; and the Chair of
the Board of Directors shall receive annual compensation of $30,000. In addition, each independent Director shall receive $2,500 attendance
at face-to-face board meetings (no compensation for telephonic or video-conference meetings).<b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_023"></span>RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2023 and 2024,
there were no related person transactions and there are not currently any proposed related person transactions that would require disclosure
under the SEC rules.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policies and Procedures for Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audit committee charter provides that our audit
committee is responsible for reviewing and approving in advance any related party transaction. This will cover, with certain exceptions
set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar
transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and
a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services
by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness
and employment by us of a related person. In determining whether to approve a proposed transaction, our Audit Committee will consider
all relevant facts and circumstances including: (i) the materiality and character of the related party&#8217;s direct or indirect interest;
(ii) the commercial reasonableness of the terms; (iii) the benefit or perceived benefit, or lack thereof, to us; (iv) the opportunity
cost of alternate transactions; and (v) the actual or apparent conflict of interest of the related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_024"></span>PROPOSAL 1:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ELECTION OF DIRECTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors currently consists of six
members: John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery. The Nominating and Corporate
Governance Committee nominated, and the Board approved and recommended, John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles,
Bettina Cockroft, and Amy Mahery for re-election. All nominees have consented to being named herein and have indicated their intention
to serve as our directors, if elected. The Board has no reason to believe that any nominee would be unable or unwilling to serve if elected.
Unless authority to do so is withheld, the persons named as proxies will vote the shares represented by such proxies for the election
of the named director nominees. In case any of the nominees becomes unavailable for election to the Board the persons named as proxies
will have full discretion and authority to vote or refrain from voting for any other nominees in accordance with their judgment. The Board
nominees, if elected, will serve until the next annual meeting of stockholders or until each successor is duly elected and qualified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Biographical information for our directors is provided
above in the section entitled &#8220;Information About Directors and Executive Officers.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A plurality of the eligible votes cast is required
to elect director nominees, and as such, the six nominees who receive the greatest number of votes cast by stockholders, entitled to vote
at the meeting, will be elected. A nominee who receives a plurality means he or she has received more votes than any other nominee for
the same director&#8217;s seat. Broker non-votes will have no effect on this proposal. <b>The Board recommends that stockholders vote
FOR each of the six nominees for election to our Board of Directors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_025"></span>PROPOSAL 2:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TO RATIFY THE APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee has selected MaloneBailey LLP
as our independent registered public accounting firm to audit our financial statements for the fiscal year ending December&#160;31, 2025.
Our stockholders are being asked to ratify this appointment. In the event that ratification of this selection of auditors is not approved
by the stockholders, we will reassess our selection of auditors. Representatives of MaloneBailey LLP are expected to be present at the
Annual Meeting, will be available to respond to appropriate questions, and will have the opportunity to make a statement at the Annual
Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aggregate fees for professional services rendered
by MaloneBailey, LLP for their services for the fiscal years ended December&#160;31, 2024 and 2023, respectively, were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Audit Fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">130,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">126,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Audit-related fees</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">167,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Tax fees</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">11,600</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">11,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">All other fees</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">0</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">TOTAL</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">308,600</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">162,300</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Audit Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Audit fees represent the aggregate fees billed for
professional services rendered by our independent accounting firm for the audit of our annual financial statements, review of financial
statements included in our quarterly reports, review of registration statements or services that are normally provided in connection with
statutory and regulatory filings or engagements for those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Audit-Related Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Audit-related fees represent the aggregate fees billed
for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and
are not reported under Audit Fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Tax Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax fees represent the aggregate fees billed for professional
services rendered by our principal accountants for tax compliance, tax advice, and tax planning for such years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>All Other Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All other fees represent the aggregate fees billed
for products and services other than the services reported in the other categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Audit Committee Pre-Approval Policies and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee on an annual basis reviews audit
and non-audit services performed by the independent auditors. All audit and non-audit services are pre-approved by the Audit Committee,
which considers, among other things, the possible effect of the performance of such services on the auditors&#8217; independence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 2 shall be approved if the number of votes
cast in favor of the action exceed the number of votes cast against the action. Broker non-votes and abstentions will not be taken into
account in determining the outcome of the proposal. <b>The Board recommends that stockholders vote FOR the ratification of the appointment
of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_026"></span>PROPOSAL 3:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>TO VOTE ON A NON-BINDING, ADVISORY RESOLUTION
TO APPROVE EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by Section 951 of the Dodd-Frank Wall
Street Reform and Consumer Protection Act and Section 14A of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
our Board is requesting stockholders to vote, on a non-binding advisory basis, to approve the compensation paid to our named executive
officers, as disclosed in this proxy statement. This proposal, commonly known as a &#8220;say-on-pay&#8221; proposal, gives stockholders
the opportunity to express their views on the compensation of our named executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This vote is not intended to address any specific
item of compensation, but rather the overall compensation of our named executive officers and our executive compensation philosophy, policies
and practices described in this proxy statement. The overall compensation of our named executive officers subject to the vote is disclosed
in this proxy statement in the subsections entitled &#8220;Executive Officer Compensation,&#8221; &#8220;Narrative Disclosure to Summary
Compensation Table,&#8221; &#8220;Outstanding Equity Awards,&#8221; and &#8220;Employment Agreements&#8221; in the section entitled &#8220;Compensation
of Directors and Executive Officers&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Compensation Committee continually reviews our
executive compensation program to determine whether such program achieves our desired goals of aligning our executive compensation strategy
and structure with our stockholders&#8217; interests and current market practices. Our executive compensation strategy and structure is
designed to motivate our executive management team to create long-term value for our stockholders through the achievement of strategic
business objectives, while effectively managing the risks and challenges inherent in a clinical stage pharmaceutical company. As our long-term
success depends on the talents of our employees, our compensation structure plays a significant role in our ability to attract, retain
and motivate the highest quality workforce in a competitive employment environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advisory Vote</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recommend stockholder approval of the compensation
of our named executive officers for the 2024&#160;fiscal year as disclosed in this proxy statement pursuant to the SEC&#8217;s compensation
disclosure rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, the Board recommends that stockholders
vote in favor of the following resolution:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;RESOLVED, that the compensation
paid to the named executive officers of CNS Pharmaceuticals, Inc., as disclosed pursuant to Item 402 of Regulation S-K, including the
compensation tables and narrative discussion is hereby APPROVED.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As this is an advisory vote, the outcome of the vote
is non-binding on us with respect to future executive compensation decisions, including those related to our named executive officers.
However, our Board and Compensation Committee will review the results of the vote and take them into account when considering future executive
compensation policies and decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Proposal 4 is approved, unless the Board modifies
its policy on the frequency of future advisory votes on the compensation of our named executive officers, the next advisory vote on the
compensation of our named executive officers will be held at our next annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 3 shall be approved if the number of votes
cast in favor of the action exceed the number of votes cast against the action. Broker non-votes and abstentions will not be taken into
account in determining the outcome of the proposal. <b>The Board recommends that stockholders vote FOR the non-binding, advisory resolution
to approve executive compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_027"></span>PROPOSAL 4:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TO VOTE ON A NON-BINDING,
ADVISORY PROPOSAL ON THE FREQUENCY OF HOLDING FUTURE VOTES REGARDING EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Section 14A of the
Exchange Act, we are required to provide our stockholders with the opportunity to vote, on a non-binding, advisory basis, for their preference
as to how frequently to hold future votes to approve, on a nonbinding, advisory basis, the compensation of our named executive officers,
which we refer to as the &#8220;say-on-pay vote&#8221;). Stockholders may indicate whether they would prefer that we conduct future say-on-pay
votes once every one, two, or three years. Stockholders also may abstain from casting a vote on this proposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has
determined that an advisory vote on executive compensation every year&#160;will permit our stockholders to provide direct input on
our executive compensation philosophy, policies, and practices as disclosed in this proxy statement, on a regular basis. This
approach is consistent with our efforts to engage in an ongoing dialogue with our stockholders on executive compensation and
corporate governance matters. An advisory vote on executive compensation occurring every year will provide our stockholders the
opportunity to provide the next advisory vote on executive compensation at our next&#160;Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This vote is advisory, which
means that the vote on executive compensation is not binding on the company, our Board of Directors, or the Compensation Committee of
the Board of Directors. We recognize that stockholders may have different views as to the best approach for the Company, and therefore
we look forward to hearing from our stockholders as to their preferences on the frequency of an advisory vote on executive compensation.
Our Board of Directors and Compensation Committee will take into account the outcome of the vote; however, when considering the frequency
of future say-on-pay votes, our Board of Directors may decide that it is in the best interests of our stockholders and the Company to
hold future say-on-pay votes more or less frequently than the frequency receiving the most votes cast by our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 4 shall be approved if the number of votes
cast in favor of the action exceed the number of votes cast against the action. Broker non-votes and abstentions will not be taken into
account in determining the outcome of the proposal. <b>The Board recommends that stockholders vote FOR the&#160;option of a vote every
year as the preferred frequency for future say-on-pay votes.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_028"></span>PROPOSAL 5:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>APPROVAL OF AMENDMENT TO THE COMPANY&#8217;S AMENDED
AND RESTATED ARTICLES OF INCORPORATION TO INCREASE THE TOTAL NUMBER OF AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 25,000,000 SHARES
TO 300,000,000 SHARES AND THE TOTAL NUMBER OF AUTHORIZED SHARES OF PREFERRED STOCK FROM 416,667 SHARES TO 5,000,000 SHARES. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board is recommending that our stockholders approve
a proposed amendment to our Amended and Restated Articles of Incorporation in substantially the form attached hereto as <span style="text-decoration: underline">Annex A</span>
(the &#8220;Share Increase Amendment&#8221;), providing for an increase in the number of our common voting shares, having a par value
of $0.001 per share, from 25,000,000 to 300,000,000 and the total number of authorized shares of preferred stock from 416,667 shares to
5,000,000 shares. If adopted and approved by the stockholders, the Share Increase Amendment will become effective upon the filing with
the Secretary of State of the State of Nevada. If the Share Increase Amendment is approved by stockholders at the Annual Meeting, we intend
to file the Share Increase Amendment as soon as practicable following the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purposes of the Proposed Amendment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 17, 2025, we filed with the Secretary of State
of the State of Nevada a Certificate of Change, pursuant to Nevada Revised Statutes 78.209, to effect a one-for-twelve (1-for-12) reverse
stock split (the &#8220;Reverse Split&#8221;) of our issued and outstanding common stock. The Reverse Split became effective on July 22,
2025. Pursuant to the Nevada Revised Statutes 78.207, our board of directors had the authority to effect the Reverse Split without stockholder
approval if the number of authorized shares of common stock and the number of outstanding shares of preferred stock were proportionally
reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Reverse Split,
each twelve pre-split shares of common stock outstanding was automatically combined into one new share of common stock without any action
on the part of the holders. The number of authorized shares of common stock was proportionately reduced from 300,000,000 to 25,000,000,
while the number of authorized shares of preferred stock was reduced from 5,000,000 to 416,667. The purpose of this Proposal 5 is to amend
our Amended and Restated Articles of Incorporation to increase our authorized shares of common stock and preferred stock to their pre-Reverse
Split levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any present plan, arrangement or understanding
to designate and issue any of the shares of common stock or preferred stock that will become available as a result of the Share Increase
Amendment. Although, at present, our Board has no immediate plans to issue the additional shares of common stock or preferred stock, it
desires to have the shares available to provide additional flexibility to use our common stock or preferred stock for business and financial
purposes in the future. The additional 275,000,000 authorized shares of common stock and 4,583,333 shares of preferred stock would be
available for issuance for various purposes, as our Board may deem advisable, such as for future financings, to satisfy the issuance of
shares of common stock or preferred stock on the conversion or exercise of our options, warrants, convertible notes, or other convertible
securities, to provide equity incentive to employees, consultants, officers and directors, to make stock-based acquisitions and for other
general corporate purposes. Furthermore, we may utilize our securities to make future acquisitions. Acquisitions can be a key component
of growth and, from time to time, consideration for acquisitions may include the issuance of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to fund-raising opportunities, we also
engage in periodic discussions with potential partners, strategic investments and acquisition candidates. If any of these discussions
came to a definitive understanding, it is possible that we could use some of the newly authorized shares in connection with one or more
such transactions. We also plan to continue to issue shares of common stock pursuant to our equity incentive plans. We currently have
no agreement, commitment, or arrangement, regarding the issuance of common stock or preferred stock in connection with one or more such
strategic transactions subsequent to the increase in the number of authorized shares. In addition, we do not have any agreements, commitments
or arrangements regarding the issuance of common stock or preferred stock in connection with a fund-raising opportunity or any other purposes
not specifically set forth in this proxy statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The newly authorized common stock and preferred stock
would be available for issuance without further action by stockholders except as required by law, our Amended and Restated Bylaws or applicable
stock exchange requirements. Any such issuance could have the effect of diluting existing stockholders. Our Amended and Restated Bylaws
do not include any preemptive or other rights of stockholders to subscribe for any shares of common stock or preferred stock which may
in the future be issued by us, which means that current stockholders do not have a prior right to purchase any new issue of common stock
or preferred stock in order to maintain their proportionate ownership of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Rights of Additional Authorized Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The additional common stock to be authorized by stockholder
approval of this Proposal 5 would have rights identical to the currently outstanding shares of our common stock. We do not have any outstanding
shares of preferred stock at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Possible Anti-Takeover Effects of the Proposed
Amendment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the corporate purposes mentioned above,
an increase in the number of authorized shares of our common stock or preferred stock may make it more difficult to, or discourage an
attempt to, obtain control of the Company by means of a takeover bid that the Board determines is not in the best interest of our Company
and our stockholders. However, our Board of Directors is not aware of any attempt to take control of our company, and our Board of Directors
has not presented this proposal with the intent that it be utilized as a type of anti-takeover device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 5 shall be approved if the number of votes
cast in favor of the action exceed the number of votes cast against the action. Broker non-votes and abstentions will not be taken into
account in determining the outcome of the proposal. <b>The Board recommends that stockholders vote FOR the approval of the amendment to
our amended and restated articles of incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares
to 300,000,000 shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_029"></span>PROPOSAL 6:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TO APPROVE AMENDMENTS TO THE 2020 PLAN INCLUDING
AN INCREASE IN THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2020 PLAN.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2025, the compensation committee of the
Board approved an amendment to the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the &#8220;2020 Plan&#8221;) to increase the number of shares
of common stock authorized for issuance under the 2020 Plan by 114,916 shares. These amendments require stockholder approval, which the
Company is seeking at this stockholders&#8217; meeting. Our 2020 Plan is attached as <span style="text-decoration: underline">Annex B</span> of this proxy statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Plan became effective in June 2020. Equity
awards have been historically and, we believe, will continue to be, an integral component of our overall compensation program for our
employees, directors and consultants. Approval of the share increase will allow us to continue to grant equity awards at levels we determine
to be appropriate in order to attract new employees and directors, retain our existing employees and directors and to provide incentives
for such persons to exert maximum efforts for our success. The share increase will allow us to continue to utilize a broad array of equity
incentives with flexibility in designing equity incentives, including stock option grants, stock appreciation rights, stock awards, and
stock unit awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe it is critical for our long-term success
that the interests of our employees and directors are tied to our success as &#8220;owners&#8221; of our business. The equity incentive
programs we have in place are intended to build stockholder value by attracting and retaining talented employees and directors. We believe
we must continue to offer competitive equity compensation packages in order to retain and motivate the talent necessary for our continued
growth and success. We carefully monitor the equity compensation and equity holdings of our employees, directors and consultants as well
as the type of equity awards we grant to ensure these awards continue to provide incentives for the recipients to work towards our success.
To date, stock options and restricted stock units have been the primary components of our equity program. The potential value of stock
options is realized only if our share price increases, and so stock options provide a strong incentive for individuals to work to build
stockholder value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the Record Date, we had 62 shares remaining
available for grant under the 2020 Plan. There are a total of 70 stock options outstanding with a weighted average exercise price of $772,562.06
per share, and restricted/performance stock units outstanding representing a total of 18 shares of our common stock. We have and we expect
to continue to experience growth in personnel as we progress our business and advance our lead drug candidate through clinical trials.
If our stockholders do not approve the amendment to the 2020 Plan, we believe that we will be unable to successfully use equity as part
of our compensation program, as most of our competitors in the industry do, putting us at a significant disadvantage. Therefore, we believe
that approval of this request is in the best interest of our stockholders and our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Key Features Designed to Protect Stockholders</b>&#8217; <b>Interests</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The design of the 2020 Plan reflects our commitment
to corporate governance and the desire to preserve stockholder value as demonstrated by the following features of the plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Independent administrator</span>. The compensation
committee of the board of directors, which is comprised solely of non-employee directors, administers the 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">No evergreen feature</span>. The maximum number of
shares available for issuance under the 2020 Plan is fixed and cannot be increased without stockholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Repricing prohibited</span>. Stockholder approval
is required for any repricing of any stock options or stock appreciation rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Limitations on Dividend Payments on Awards</span>.
Dividends and dividend equivalents on all stock units and stock awards are paid only to the extent the awards vest, and no dividends or
dividend equivalents are ever paid on stock options or stock appreciation rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">No discount awards; maximum term specified</span>.
Stock options and stock appreciation rights must have an exercise price or base price no less than the fair market value on the date the
award is granted and a term no longer than ten years&#8217; duration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Award design flexibility</span>. Different kinds of
awards may be granted under the 2020 Plan, giving us the flexibility to design our equity incentives to compliment the other elements
of compensation and to support the attainment of our strategic goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Share counting</span>. The number of shares available
for grant under the 2020 Plan is reduced by the gross number of shares subject to awards, and shares withheld for taxes in connection
with awards or tendered in payment of an option&#8217;s exercise price cannot be used for future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Non-employee director limits</span>. The 2020 Plan
contains a limit on the compensation that may be paid to any non-employee member of our Board in any calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">No tax gross-ups</span>. The 2020 Plan does not provide
for tax gross-ups.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Fixed term</span>. The 2020 Plan has a fixed term
of ten years from its initial effective date, or April 6, 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Description of the 2020 Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Plan is a stock-based compensation plan that
provides for discretionary grants of stock options, stock awards, stock unit awards and stock appreciation rights to key employees, non-employee
directors and consultants. The material features of the 2020 Plan are outlined below. The following description of the 2020 Plan is a
summary only and is qualified in its entirety by reference to the complete text of the 2020 Plan. Stockholders are urged to read the actual
text of the 2020 Plan in its entirety, which is appended to this Proxy Statement as <span style="text-decoration: underline">Annex B</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Administration.</b>&#160;The 2020 Plan is administered
by our compensation committee of the board of directors (we refer to the body administering the 2020 Plan as the &#8220;Committee&#8221;).
The Committee, which is comprised of directors who satisfy the non-employee director definition under Rule 16b-3 of the Securities Exchange
Act of 1934,&#160;has full authority to select the individuals who will receive awards under the 2020 Plan, determine the form and amount
of each of the awards to be granted and establish the terms and conditions of awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Limit on Non-Employee Director Compensation. </b>Under
the 2020 Plan, the following limits apply to non-employee directors. The aggregate value of all compensation granted or paid, as applicable,
to any individual for service as a non-employee director with respect to any calendar year, including awards granted under the 2020 Plan
and cash fees paid to such non-employee director, will not exceed $300,000 in total value. For purposes of these limitations, the value
of awards is calculated based on the grant date fair value of such awards for financial reporting purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Number of Shares of Common Stock.</b>&#160;As of
the Record Date, 62 shares remain available for issuance under the 2020 Plan, which currently provides for up to 145 shares to be issued.
If this proposal is approved, the number of shares of the common stock that may be issued under the 2020 Plan will be 115,061 (this includes
the 114,916 share increase being requested in this proxy statement), of which 114,978 shares will be available for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares issuable under the 2020 Plan may be authorized
but unissued shares or treasury shares. If there is a lapse, forfeiture, expiration, termination or cancellation of any award made under
the 2020 Plan for any reason, the shares subject to the award will again be available for issuance. Any shares subject to an award that
are delivered to us by a participant, or withheld by us on behalf of a participant, as payment for an award or payment of withholding
taxes due in connection with an award will not again be available for issuance, and all such shares will count toward the number of shares
issued under the 2020 Plan. The number of shares of common stock issuable under the 2020 Plan is subject to adjustment, in the event of
any reorganization, recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision,
consolidation or exchange of shares, any change in the capital structure of the company or any similar corporate transaction. In each
case, the Committee has the discretion to make adjustments it deems necessary to preserve the intended benefits under the 2020 Plan. No
award granted under the 2020 Plan may be transferred, except by will, or the laws of descent and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Eligibility.</b>&#160;All employees designated
as key employees for purposes of the 2020 Plan, non-employee directors and consultants are eligible to receive awards under the 2020
Plan. As of October 10, 2025, 6&#160;employees and all&#160;non-employee directors were eligible to participate in the 2020 Plan.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Awards to Participants.</b>&#160;The 2020 Plan
provides for discretionary awards of stock options, stock awards, stock unit awards and stock appreciation rights to participants. Each
award made under the 2020 Plan will be evidenced by a written award agreement specifying the terms and conditions of the award as determined
by the Committee in its sole discretion, consistent with the terms of the 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options</i>.&#160;The Committee has the discretion
to grant non-qualified stock options or incentive stock options to participants and to set the terms and conditions applicable to the
options, including the type of option, the number of shares subject to the option and the vesting schedule; provided that the exercise
price of each stock option will be the closing price of the common stock on the date on which the option is granted (&#8220;fair market
value&#8221;), each option will expire ten years from the date of grant and no dividend equivalents may be paid with respect to stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, an incentive stock option granted to
a key employee is subject to the following rules: (i) the aggregate fair market value (determined at the time the option is granted) of
the shares of common stock with respect to which incentive stock options are exercisable for the first time by a key employee during any
calendar year (under all incentive stock option plans of the company and its subsidiaries) cannot exceed $100,000, and if this limitation
is exceeded, that portion of the incentive stock option that does not exceed the applicable dollar limit will be an incentive stock option
and the remainder will be a non-qualified stock option; (ii) if an incentive stock option is granted to a key employee who owns stock
possessing more than 10% of the total combined voting power of all class of stock of the company, the exercise price of the incentive
stock option will be 110% of the closing price of the common stock on the date of grant and the incentive stock option will expire no
later than five years from the date of grant; and (iii) no incentive stock option can be granted after ten years from the initial effective
date of the 2020 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Appreciation Rights</i>. The Committee has
the discretion to grant stock appreciation rights to participants. The Committee determines the exercise price for a stock appreciation
right, which cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise of a stock
appreciation right, we will pay the participant in common stock or in cash, at our discretion, an amount equal to the product of (1) the
excess of the per share fair market value of our common stock on the date of exercise over the exercise price, multiplied by (2) the number
of shares of common stock with respect to which the stock appreciation right is exercised. The Committee has the discretion to set the
terms and conditions applicable to the award, including the number of shares subject to the stock appreciation right and the vesting schedule,
provided that each stock appreciation right will expire not more than ten years from the date of grant and no dividends or dividend equivalents
shall be paid with respect to any stock appreciation right prior to the exercise of the stock appreciation right.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Awards</i>.&#160;The Committee has the discretion
to grant stock awards to participants. Stock awards will consist of shares of common stock granted without any consideration from the
participant or shares sold to the participant for appropriate consideration as determined by the Board. The number of shares awarded to
each participant, and the restrictions, terms and conditions of the award, will be at the discretion of the Committee. Subject to the
restrictions, a participant will be a stockholder with respect to the shares awarded to him or her and will have the rights of a stockholder
with respect to the shares, including the right to vote the shares and receive dividends on the shares; provided that dividends otherwise
payable on any stock award subject to restrictions will be held by us and will be paid to the holder of the stock award only to the extent
the restrictions on such stock award lapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Units.</i>&#160;The Committee has the discretion
to grant stock unit awards to participants. Each stock unit entitles the participant to receive, on a specified date or event set forth
in the award agreement, one share of common stock or cash equal to the fair market value of one share on such date or event, as provided
in the award agreement. The number of stock units awarded to each participant, and the terms and conditions of the award, will be at the
discretion of the Committee. Unless otherwise specified in the award agreement, a participant will not be a stockholder with respect to
the stock units awarded to him prior to the date they are settled in shares of common stock. The award agreement may provide that until
the restrictions on the stock units lapse, the participant will be paid an amount equal to the dividends that would have been paid had
the stock units been actual shares; provided that such dividend equivalents will be held by us and paid only to the extent the restrictions
lapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Award Limits</i>. The 2020 Plan contains a limit
on the number of shares of common stock as to which any one recipient may receive stock options or stock appreciation rights in any calendar
year to $1,500,000 in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial
reporting purposes). In addition, the 2020 Plan contains a limit on the number of shares of common stock that may be used for stock awards
and/or stock unit awards to any one recipient in any calendar year to $1,500,000 in total value (calculating the value of any such awards
based on the grant date fair value of such awards for financial reporting purposes). We believe these limits will prevent the volatility
of our stock price from effecting our ability to plan future awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Payment for Stock Options and Withholding Taxes.</b>&#160;The
Committee may make one or more of the following methods available for payment of any award, including the exercise price of a stock option,
and for payment of the tax obligation associated with an award: (i) cash; (ii) cash received from a broker-dealer to whom the holder has
submitted an exercise notice together with irrevocable instructions to deliver promptly to us the amount of sales proceeds from the sale
of the shares subject to the award to pay the exercise price or withholding tax; (iii) by directing us to withhold shares of common stock
otherwise issuable in connection with the award having a fair market value equal to the amount required to be withheld; and (iv) by delivery
of previously acquired shares of common stock that are acceptable to the Committee and that have an aggregate fair market value on the
date of exercise equal to the exercise price or withholding tax, or certification of ownership by attestation of such previously acquired
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Provisions Relating to a &#8220;Change in Control&#8221;
of the Company.</b>&#160;Notwithstanding any other provision of the 2020 Plan or any award agreement, in the event of a &#8220;Change in
Control&#8221; of the company, the Committee has the discretion to provide that all outstanding awards will become fully exercisable, all
restrictions applicable to all awards will terminate or lapse, and performance goals applicable to any stock awards will be deemed satisfied
at the target level. In addition, upon such Change in Control, the Committee has sole discretion to provide for the purchase of any outstanding
stock option for cash equal to the difference between the exercise price and the then fair market value of the common stock subject to
the option had the option been currently exercisable, make such adjustment to any award then outstanding as the Committee deems appropriate
to reflect such Change in Control and cause any such award then outstanding to be assumed by the acquiring or surviving corporation after
such Change in Control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Amendment of Award Agreements; Amendment and Termination of the 2020
Plan; Term of the 2020 Plan.</b>&#160;The Committee may amend any award agreement at any time, provided that no amendment may adversely
affect the right of any participant under any agreement in any material way without the written consent of the participant, unless such
amendment is required by applicable law, regulation or stock exchange rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may terminate, suspend or amend the 2020
Plan, in whole or in part, from time to time, without the approval of the stockholders, unless such approval is required by applicable
law, regulation or stock exchange rule, and provided that no amendment may adversely affect the right of any participant under any outstanding
award in any material way without the written consent of the participant, unless such amendment is required by applicable law, regulation
or rule of any stock exchange on which the shares are listed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the foregoing, neither the 2020 Plan
nor any outstanding award agreement can be amended in a way that results in the repricing of a stock option. Repricing is broadly defined
to include reducing the exercise price of a stock option or stock appreciation right or cancelling a stock option or stock appreciation
right in exchange for cash, other stock options or stock appreciation rights with a lower exercise price or other stock awards. (This
prohibition on repricing without stockholder approval does not apply in case of an equitable adjustment to the awards to reflect changes
in the capital structure of the company or similar events.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No awards may be granted under the 2020 Plan on or
after the tenth anniversary of the initial effective date of the 2020 Plan, or April 6, 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>U.S. Federal Income Tax Consequences</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information set forth below is a summary only
and does not purport to be complete. The information is based upon current U.S. federal income tax rules and therefore is subject to change
when those rules change. Because the tax consequences to any recipient of an award may depend on his or her particular situation, each
recipient should consult the recipient&#8217;s tax adviser regarding the federal, state, local, and other tax consequences of the grant
or exercise of an award or the disposition of shares acquired as a result of an award. The 2020 Plan will not be qualified under the provisions
of section 401(a) of the Code and will not be subject to any of the provisions of the Employee Retirement Income Security Act of 1974,
as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Non-Qualified Stock Options</i>. A participant
will not recognize any income at the time of grant. On the date the participant exercises the non-qualified stock option, the participant
will recognize ordinary income in an amount equal to the excess of the fair market value of the shares on the date of exercise over the
exercise price. The participant will be responsible for remitting to us the withholding tax obligation that arises at the time the option
is exercised. We generally will receive a tax deduction for the same amount of ordinary income recognized by the participant. When the
participant sells these shares, any gain or loss recognized by the participant is treated as either short-term or long-term capital gain
or loss depending on whether the participant has held the shares more than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Incentive Stock Options</i><b>.</b> A participant
will not recognize any income at the time of grant. If the participant is issued shares pursuant to the exercise of an incentive stock
option, and if the participant does not make a disqualifying disposition of the shares within one year after the date of exercise or within
two years after the date of grant, the participant will not recognize any income, for federal income tax purposes, at the time of the
exercise. When the participant sells the shares issued pursuant to the incentive stock option, the participant will be taxed, for federal
income tax purposes, as a long-term capital gain on any amount recognized by the participant in excess of the exercise price, and any
loss sustained by the participant will be a long-term capital loss. No deduction will be allowed to us for federal income tax purposes.
If, however, the participant sells the shares before the expiration of the holding periods, the participant will recognize ordinary income
on the difference between the exercise price and the fair market value at exercise, and we generally will receive a tax deduction in the
same amount. Upon exercise of an incentive stock option, the excess of the fair market value over the exercise price is an item of tax
preference to the participant for purposes of determining the alternative minimum tax.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to qualify as an incentive stock option, the option must be exercised
within three months after the participant&#8217;s termination of employment for any reason other than death or disability and within one
year after termination of the participant&#8217;s employment due to disability. If the option is not exercised within this time period,
it will be treated as a non-qualified stock option and taxed accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Awards/Stock Units</i><b>. </b>If a participant
receives a stock award, the participant will recognize ordinary income upon becoming entitled to transfer the shares at the end of the
restriction period without forfeiture. A participant generally will recognize ordinary income when he receives cash or shares pursuant
to the settlement of stock units, provided that if the shares are subject to any further restrictions on transfer, the participant will
recognize ordinary income upon becoming entitled to transfer the shares at the end of the restriction period without forfeiture. The amount
of income the participant recognizes will be equal to the fair market value of the shares on such date, or the amount of cash received,
less the amount paid by the participant for the shares. This amount will also be the participant&#8217;s tax basis for the shares. The
participant will be responsible for remitting to us the withholding tax obligation that arises at the time the ordinary income is recognized.
In addition, the holding period begins on the day the restrictions lapse, or the date the shares are received if not subject to any restrictions,
for purposes of determining whether the participant has long-term or short-term capital gain or loss on a subsequent sale of the shares.
We generally will be entitled to a deduction with respect to the ordinary income recognized by the participant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a participant who receives a stock award subject
to restrictions makes an election under Section 83(b) of the Code within 30 days after the date of the grant, the participant will have
ordinary income equal to the fair market value on the date of grant, less the amount paid by the participant for the shares, and the participant
will recognize no additional income until the participant subsequently sells the shares. The participant will be responsible for remitting
to us the withholding tax obligation that arises at the time the ordinary income is recognized. When the participant sells the shares,
the tax basis will be equal to the fair market value on the date of grant and the holding period for capital gains purposes begins on
the date of the grant. If the participant forfeits the shares subject to the Section 83(b) election, the participant will not be entitled
to any deduction, refund, or loss for tax purposes (other than a capital loss with respect to the amount of ordinary income previously
recognized by the participant), and we will have to include the amount that was previously deducted from our gross income in the taxable
year of the forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Appreciation Rights</i><b>. </b>A participant
will not recognize any income at the time of the grant of a stock appreciation right. Upon exercise of the stock appreciation right, the
participant will recognize ordinary income equal to the amount received upon exercise. The participant will be responsible for remitting
to us the withholding tax obligation that arises at the time the ordinary income is recognized. We generally will be entitled to a deduction
with respect to the ordinary income recognized by the participant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Awards Granted Under the 2020 Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">The following awards
have been granted under the Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 49%; text-align: center"><span style="font-size: 10pt">Name and Position</span></td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 49%"><span style="font-size: 10pt">Number of Units (1)(2)</span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">John Climaco, President - Chief Executive Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">9,769 Stock Options and 7 Restricted Stock Units</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Christopher S. Downs, Chief Financial Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4,888 Stock Options and 7 Restricted Stock Units</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Sandra Silberman, Chief Medical Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,448 Stock Options and 5 Restricted Stock Units</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Executive Group:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">17,105 Stock Options and 19 Restricted Stock Units</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Non-Executive Director Group:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">7,606 Stock Options and 5 Restricted Stock Units</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><span style="font-size: 10pt">Non-Executive Officer Employee Group:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4,895 Stock Options and 10 Restricted Stock Units</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The table includes grants approved by the compensation committee on
March 11, 2025 but which are subject to stockholder approval of this Proposal 6 increasing the shares available under 2020 Plan. These
grants include options for 9,761 shares for Mr. Climaco, 4,881 for Mr. Downs, 2,441 for Ms. Silberman, and 4,882 for other members of
the Non-Executive Officer Employee Group. These options have a strike price of $30.00 and a 10-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The table includes grants recommended by the compensation committee
and approved by the board of directors for non-employee directors on June 6, 2025 but which are subject to stockholder approval of this
Proposal 6 increasing the shares under 2020 Plan. These grants include options for 1,517 shares each for Ms. Charles, Dr. Cockroft, Dr.
Gumulka, Mr. Keyes and Ms. Mahery. These options have a strike price of $12.12 and a 10-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 8, 2025, the last reported sales price
for the common stock was $10.57&#160;per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>New Plan Benefits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is not possible at this time to determine the specific
awards that will be made in the future under the 2020 Plan, including with regard to the individuals and groups listed above under the
heading &#8220;<i>Awards Granted Under the 2020 Plan</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b>Securities Authorized for Issuance
under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The following table sets forth information
regarding our equity compensation plans at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Plan category</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of securities to be issued upon exercise
    of outstanding options,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>warrants and rights</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(a)</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted-average exercise price of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>outstanding options, warrants and rights</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(b)</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of securities (by class) remaining available
    for future issuance under equity compensation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>plans (excluding securities reflected in column
    (a))</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(c)</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#65279;</span><span style="font-size: 10pt">Equity compensation plans approved by security holders (1)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">98</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">$772,562.06</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">62</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Equity compensation plans not approved by security holders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents shares of common stock issuable upon exercise of outstanding stock options and rights under our 2017 and 2020 Stock Plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of this Proposal 6 requires the number
of votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal. <b>The Board recommends that stockholders vote FOR the amendments to the 2020 Plan including an increase in
the number of shares of common stock authorized for issuance under the 2020 Plan.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_030"></span>PROPOSAL 7:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AUTHORIZATION TO ADJOURN THE ANNUAL MEETING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Annual Meeting is convened and a quorum is
present, but there are not sufficient votes to approve the above proposals, one or more of our proxy holders may move to adjourn the Annual
Meeting at that time in order to enable our Board to solicit additional proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In this proposal, we are asking our stockholders to
authorize one or more of our proxy holders to adjourn the Annual Meeting to another time and place, if necessary, to solicit additional
proxies in the event that there are not sufficient votes to approve the above proposals. If our stockholders approve this proposal, one
or more of our proxy holders can adjourn the Annual Meeting and any adjourned session of the Annual Meeting to allow for additional time
to solicit additional proxies, including the solicitation of proxies from our stockholders that have previously voted. Among other things,
approval of this proposal could mean that, even if we had received proxies representing a sufficient number of votes to defeat any or
all of the above proposals, we could adjourn the Annual Meeting without a vote on such proposals and seek to convince our stockholders
to change their votes in favor of such proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If it is necessary to adjourn the Annual Meeting,
no notice of the adjourned meeting is required to be given to our stockholders, other than an announcement at the Annual Meeting of the
time and place to which the Annual Meeting is adjourned, so long as the meeting is adjourned for 60 days or less and no new record date
is fixed for the adjourned meeting. At the adjourned meeting, we may transact any business which might have been transacted at the original
meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Vote Required and Recommendation of the Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approval of Proposal 7 requires the number of
votes cast in favor of the proposal to exceed the number of votes cast against the action. Abstentions and broker non-votes will have
no effect on this proposal. <b>The Board recommends that stockholders vote FOR the approval to authorize the adjournment of the Annual
Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the above proposals.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_031"></span>AUDIT COMMITTEE REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee assists the Board of Directors
with its oversight responsibilities regarding the Company&#8217;s financial reporting process. The Company&#8217;s management is responsible
for the preparation, presentation and integrity of the Company&#8217;s financial statements and the reporting process, including the Company&#8217;s
accounting policies, internal control over financial reporting and disclosure controls and procedures. MaloneBailey LLP, the Company&#8217;s
independent registered public accounting firm, is responsible for performing an audit of the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed and discussed with management and
MaloneBailey LLP the Company&#8217;s audited financial statements. We discussed with MaloneBailey LLP the overall scope and plans of their
audit. We met with MaloneBailey LLP, with and without management present, to discuss the results of its examinations, its evaluation of
the Company&#8217;s internal controls, and the overall quality of the Company&#8217;s financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to the fiscal year ended December 31,
2024, the Audit Committee (i) reviewed and discussed with management the Company&#8217;s audited financial statements as of December 31,
2024, and for the year then ended; (ii) discussed with MaloneBailey LLP the matters required by Public Company Accounting Oversight Board
(PCAOB) and the Securities and Exchange Commission; (iii) received the written disclosures and the letter from MaloneBailey LLP required
by applicable requirements of the PCAOB regarding MaloneBailey LLP&#8217;s communications with the Audit Committee regarding independence;
and (iv) discussed with MaloneBailey LLP their independence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the review and discussions described above,
the Audit Committee recommended to the Company&#8217;s Board of Directors that the Company&#8217;s audited financial statements be included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, for filing with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Jeffry Keyes (Chair)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Faith Charles</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Amy Mahery</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_032"></span>AVAILABILITY OF ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of our 2024 Annual Report on Form 10-K has
been mailed concurrently with this proxy statement to stockholders entitled to notice of and to vote at the Annual Meeting, provided that
we have not included the exhibits to the Form 10-K. We will provide copies of these exhibits without cost upon request by eligible stockholders.
Requests for copies of such exhibits should be mailed to CNS Pharmaceuticals,&#160;Inc., 2100 West Loop South, Suite 900, Houston, TX
77027, Attention: Corporate Secretary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_033"></span>OTHER PROPOSED ACTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors does not intend to bring any
other matters before the Annual Meeting, nor does it know of any matters which other persons intend to bring before the Annual Meeting.
If, however, other matters not mentioned in this proxy statement properly come before the Annual Meeting, the persons named in the accompanying
form of proxy will vote thereon in accordance with the recommendation of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_034"></span>HOUSEHOLDING OF PROXY MATERIALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC has adopted rules that permit companies and
intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing
the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as
&#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This year, a number of brokers with account holders
who are the Company&#8217;s stockholders may be &#8220;householding&#8221; our proxy materials. A single copy of the proxy materials may
be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders.
Once you have received notice from your broker that they will be householding communications to your address, householding will continue
until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding
and would prefer to receive a separate copy of the proxy materials, please (1) notify your broker, or (2) direct your written request
to CNS Pharmaceuticals,&#160;Inc., 2100 West Loop South, Suite 900, Houston, TX 77027, Attention: Corporate Secretary. Stockholders who
currently receive multiple copies of the proxy materials at their address and would like to request householding of their communications
should contact their brokers. In addition, upon written request to the address set forth above, we will promptly deliver a separate copy
of the proxy materials to any stockholder at a shared address to which a single copy of the documents was delivered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_035"></span>STOCKHOLDER PROPOSALS AND SUBMISSIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to be eligible for inclusion in our proxy
statement and form of proxy for our 2026 Annual Meeting, a proposal of a stockholder, including the submission of a stockholder nominee
for election to our Board of Directors, must be received at our principal executive offices located in Houston, Texas no later than June
22, 2026 (the &#8220;Deadline&#8221;). For any proposal that a stockholder wishes to propose for consideration at the 2026 Annual Meeting
but does not wish to include in the proxy materials for that meeting, our Amended and Restated Bylaws require a notice of the proposal
to be delivered not less than 120 days prior to the anniversary of the mailing date of our proxy materials for the preceding annual meeting
of stockholders. The notice of the proposal also must comply with the content requirements for such notices set forth in our Amended and
Restated Bylaws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whether or not you expect to be present at the Annual
Meeting, please sign and return the enclosed proxy promptly. Your vote is important. If you are a stockholder of record and attend the
Annual Meeting and wish to vote in person, you may withdraw your proxy at any time prior to the vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 62%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">By Order of the Board of Directors</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CNS PHARMACEUTICALS,&#160;INC.</p></td>
    <td style="width: 38%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><span style="text-decoration: underline">/s/ JOHN CLIMACO</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">John Climaco</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Houston, Texas</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>October 24, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_036"></span>ANNEX A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATE OF AMENDMENT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CNS PHARMACEUTICALS, INC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">CNS Pharmaceuticals, Inc., a corporation
organized and existing under the laws of the State of Nevada (the &#8220;Company&#8221;) for the purpose of amending its Amended and Restated
Articles of Incorporation in accordance with Chapter 78 of the Nevada Revised Statutes, does hereby make and execute this Certificate
of Amendment to the Amended and Restated Articles of Incorporation, as amended, and does hereby certify that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1. The provisions of the present
Section 3.1 of the Amended and Restated Articles of Incorporation of the Corporation are amended by amending and restating Section 3.1
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall have
the authority to issue Three Hundred Million (300,000,000) shares of common stock having a par value of $0.001 per share (the &#8220;Common
Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The provisions of the present
Section 3.2 of the Amended and Restated Articles of Incorporation of the Corporation are amended by amending and restating the first sentence
of Section 3.2, with no changes to be made to the previous or subsequent sentences and provisions of Section 3.2:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall have
the authority to issue Five Million (5,000,000) shares of preferred stock having a par value of $0.001 per share (the &#8220;Preferred
Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. The foregoing amendment
has been duly adopted in accordance NRS 78.385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. This amendment shall be effective
as of ____ p.m., Eastern Time, on _____.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, I have signed
this Certificate this _______ day of ____.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 46%">&#160;</td>
    <td style="width: 54%"><span style="font-size: 10pt">CNS Pharmaceuticals, Inc.<br/>
<br/>
<br/>
By: _________________________<br/>
&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name: John Climaco<br/>
&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title: Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"></span></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><span id="a_037"></span>Annex B</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CNS PHARMACEUTICALS, INC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2020 EQUITY PLAN</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Amended and Restated)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">______________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 1.</span></td>
    <td><span style="font-size: 10pt">Establishment and Purpose.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 The Board of Directors
of CNS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the
&#8220;Plan&#8221;) effective as of April 6, 2020, which was approved by the Company&#8217;s stockholders at the Company&#8217;s
annual meeting on June 8, 2020. The Plan was amended effective as of August 9, 2023, as of March 26, 2024, and on November 17, 2025,
subject to approval by the Company&#8217;s stockholders at the Company&#8217;s annual meeting on November 17, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2 The purpose of the Plan
is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to
recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and Consultants, and to provide
such Key Employees, Directors and Consultants with additional incentive to expand and improve the profits and achieve the objectives
of the Company and its Subsidiaries, by providing such Key Employees, Directors and Consultants with the opportunity to acquire or
increase their proprietary interest in the Company through receipt of Awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 2.</span></td>
    <td><span style="font-size: 10pt">Definitions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As used in the Plan, the following
terms shall have the meanings set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.1&#160;&#8220;<span style="text-decoration: underline">Award</span>&#8221; means
any award or benefit granted under the Plan, which shall be a Stock Option, a Stock Award, a Stock Unit Award or an SAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2&#160;&#8220;<span style="text-decoration: underline">Award Agreement</span>&#8221;
means, as applicable, a Stock Option Agreement, Stock Award Agreement, Stock Unit Award Agreement or SAR Agreement evidencing an Award
granted under the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&#160;&#8220;<span style="text-decoration: underline">Board</span>&#8221;
means the Board of Directors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4&#160;&#8220;<span style="text-decoration: underline">Change in
Control</span>&#8221; has the meaning set forth in Section 8.2 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.5 &#8220;<span style="text-decoration: underline">Code</span>&#8221;
means the Internal Revenue Code of 1986, as amended from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.6 &#8220;<span style="text-decoration: underline">Committee</span>&#8221;
means the Compensation Committee of the Board or such other committee as may be designated by the Board from time to time to administer
the Plan, or, if no such committee has been designated at the time of any grants, it shall mean the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.7 &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;
means the Common Stock, par value $0.001 per share, of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.8 &#8220;<span style="text-decoration: underline">Company&#8221;</span>
means CNS Pharmaceuticals, Inc., a Nevada corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.9 &#8220;<span style="text-decoration: underline">Consultant</span>&#8221;
means any person, including an advisor, who is engaged by the Company or an affiliate to render consulting or advisory services and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director
to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant
under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale
of the Company&#8217;s securities to such person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.10 &#8220;<span style="text-decoration: underline">Director</span>&#8221;
means a director of the Company who is not an employee of the Company or a Subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.11 &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;
means the Securities Exchange Act of 1934, as amended from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.12 &#8220;<span style="text-decoration: underline">Fair Market Value</span>&#8221;
means as of any date, the closing price of a share of Common Stock on the national securities exchange on which the Common Stock is listed,
or, if the Common Stock is not listed on a national securities exchange, the over-the-counter market on which the Common Stock trades,
or, if the Common Stock is not listed on a national securities exchange or an over-the-counter market, as determined by the Board as
of such date, or, if no trading occurred on such date, as of the trading day immediately preceding such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.13 &#8220;<span style="text-decoration: underline">Incentive Stock
Option</span>&#8221; or &#8220;<span style="text-decoration: underline">ISO</span>&#8221; means a Stock Option granted under Section 5 of the Plan that meets the requirements of
Section 422(b) of the Code or any successor provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.14 &#8220;<span style="text-decoration: underline">Key Employee</span>&#8221;
means an employee of the Company or any Subsidiary selected to participate in the Plan in accordance with Section 3. A Key Employee may
also include a person who is granted an Award (other than an Incentive Stock Option) in connection with the hiring of the person prior
to the date the person becomes an employee of the Company or any Subsidiary, provided that such Award shall not vest prior to the commencement
of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.15 &#8220;<span style="text-decoration: underline">Non-Qualified
Stock Option</span>&#8221; or &#8220;<span style="text-decoration: underline">NSO</span>&#8221; means a Stock Option granted under Section 5 of the Plan that is not an Incentive
Stock Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.16 &#8220;<span style="text-decoration: underline">Participant</span>&#8221;
means a Key Employee, Director or Consultant selected to receive an Award under the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.17 &#8220;<span style="text-decoration: underline">Plan</span>&#8221;
means the CNS Pharmaceuticals, Inc. 2020 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.18 &#8220;<span style="text-decoration: underline">Stock Appreciation
Right</span>&#8221; or &#8220;<span style="text-decoration: underline">SAR</span>&#8221; means a grant of a right to receive shares of Common Stock or cash under Section 8 of the
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.19 &#8220;<span style="text-decoration: underline">Stock Award</span>&#8221;
means a grant of shares of Common Stock under Section 6 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.20 &#8220;<span style="text-decoration: underline">Stock Option</span>&#8221;
means an Incentive Stock Option or a Non-Qualified Stock Option granted under Section 5 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.21 &#8220;<span style="text-decoration: underline">Stock Unit Award</span>&#8221;
means a grant of a right to receive shares of Common Stock or cash under Section 7 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.22 &#8220;<span style="text-decoration: underline">Subsidiary</span>&#8221;
means an entity of which the Company is the direct or indirect beneficial owner of not less than 50% of all issued and outstanding equity
interest of such entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 3.</span></td>
    <td><span style="font-size: 10pt">Administration.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <span style="text-decoration: underline">The
Committee</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Plan shall be administered
by the Committee, which shall be comprised of at least two members of the Board who satisfy the &#8220;non-employee director&#8221; definition
set forth in Rule 16b-3 under the Exchange Act, unless the Board otherwise determines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">3.2 <span style="text-decoration: underline">Authority of the
Committee</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Committee, in
its sole discretion, shall determine the Key Employees, Consultants and Directors to whom, and the time or times at which Awards will
be granted, the form and amount of each Award, the expiration date of each Award, the time or times within which the Awards may be exercised,
the cancellation of the Awards and the other limitations, restrictions, terms and conditions applicable to the grant of the Awards. The
terms and conditions of the Awards need not be the same with respect to each Participant or with respect to each Award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) To the extent permitted
by applicable law, regulation, and rules of a stock exchange on which the Common Stock is listed or traded, the Committee may delegate
its authority to grant Awards to Key Employees and to determine the terms and conditions thereof to such officer of the Company as it
may determine in its discretion, on such terms and conditions as it may impose, except with respect to Awards to officers subject to Section
16 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) The Committee may,
subject to the provisions of the Plan, establish such rules and regulations as it deems necessary or advisable for the proper administration
of the Plan, and may make determinations and may take such other action in connection with or in relation to the Plan as it deems necessary
or advisable. Each determination or other action made or taken pursuant to the Plan, including interpretation of the Plan and the specific
terms and conditions of the Awards granted hereunder, shall be final and conclusive for all purposes and upon all persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) No member of the
Board or the Committee shall be liable for any action taken or determination made hereunder in good faith. Service on the Committee shall
constitute service as a Director so that the members of the Committee shall be entitled to indemnification and reimbursement as Directors
of the Company pursuant to the Company&#8217;s Amended and Restated Articles of Incorporation and Amended and Restated Bylaws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3 <span style="text-decoration: underline">Award
Agreements</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) Each Award shall
be evidenced by a written Award Agreement specifying the terms and conditions of the Award. In the sole discretion of the Committee, the
Award Agreement may condition the grant of an Award upon the Participant&#8217;s entering into one or more of the following agreements
with the Company: (i) an agreement not to compete with the Company and its Subsidiaries which shall become effective as of the date of
the grant of the Award and remain in effect for a specified period of time following termination of the Participant&#8217;s employment
with the Company; (ii) an agreement to cancel any employment agreement, fringe benefit or compensation arrangement in effect between the
Company and the Participant; and (iii) an agreement to retain the confidentiality of certain information. Such agreements may contain
such other terms and conditions as the Committee shall determine. If the Participant shall fail to enter into any such agreement at the
request of the Committee, then the Award granted or to be granted to such Participant shall be forfeited and cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 4.</span></td>
    <td><span style="font-size: 10pt">Shares of Common Stock Subject to Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <span style="text-decoration: underline">Total Number of
Shares</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The total number
of shares of Common Stock that may be issued under the Plan shall be 115,061 (which reflects the 145 shares previously authorized under
the Plan and 114,916 shares to be issued under the Plan pursuant to this amendment and restatement). Such shares may be either authorized
but unissued shares or treasury shares, and shall be adjusted in accordance with the provisions of Section 4.3 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The number of shares
of Common Stock delivered by a Participant or withheld by the Company on behalf of any such Participant as full or partial payment of
an Award, including the exercise price of a Stock Option or of any required withholding taxes, shall not again be available for issuance
pursuant to subsequent Awards, and shall count towards the aggregate number of shares of Common Stock that may be issued under the Plan.
Any shares of Common Stock purchased by the Company with proceeds from a Stock Option exercise shall not again be available for issuance
pursuant to subsequent Awards, shall count against the aggregate number of shares that may be issued under the Plan and shall not increase
the number of shares available under the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) If there is a lapse,
forfeiture, expiration, termination or cancellation of any Award for any reason (including for reasons described in Section 3.3), or if
shares of Common Stock are issued under such Award and thereafter are reacquired by the Company pursuant to rights reserved by the Company
upon issuance thereof, the shares of Common Stock subject to such Award or reacquired by the Company shall again be available for issuance
pursuant to subsequent Awards, and shall not count towards the aggregate number of shares of Common Stock that may be issued under the
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <span style="text-decoration: underline">Shares Under
Awards</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Of the shares of Common Stock
authorized for issuance under the Plan pursuant to Section 4.1:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The maximum number
of shares of Common Stock as to which a Key Employee may receive Stock Options or SARs in any calendar year will not exceed $1,500,000
in total value (calculating the value of any such Stock Options or SARs based on the grant date fair value of such Stock Options or SARs
for financial reporting purposes). For the avoidance of doubt, shares of Common Stock that may be used for Stock Awards and/or Stock Unit
Awards pursuant to Section 4.2(c) shall not be included in the foregoing calculation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The maximum number
of shares of Common Stock that may be subject to Stock Options (ISOs and/or NSOs) is the total number of shares set forth in Section 4.1(a).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) The maximum number
of shares of Common Stock that may be used for Stock Awards and/or Stock Unit Awards that may be granted to any Key Employee in any calendar
year will not exceed $1,500,000 in total value (calculating the value of any such Stock Awards and/or Stock Unit Awards based on the grant
date fair value of such Stock Awards and/or Stock Unit Awards for financial reporting purposes). For the avoidance of doubt, shares of
Common Stock that may be used for Stock Options and/or SARs pursuant to Section 4.2(a) shall not be included in the foregoing calculation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) The maximum number
of shares of Common Stock subject to Awards granted under the Plan or otherwise during any one calendar year to any Director, taken together
with any cash fees paid by the Company to such Director during such calendar year for service on the Board, will not exceed $300,000 in
total value (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The numbers of shares described herein shall be as
adjusted in accordance with Section 4.3 of the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">4.3 <span style="text-decoration: underline">Adjustment</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event of any reorganization,
recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision, consolidation
or exchange of shares, any change in the capital structure of the Company or any similar corporate transaction, the Committee shall make
such adjustments as it deems appropriate, in its sole discretion, to preserve the benefits or intended benefits of the Plan and Awards
granted under the Plan. Such adjustments may include: (a) adjustment in the number and kind of shares reserved for issuance under the
Plan; (b) adjustment in the number and kind of shares covered by outstanding Awards; (c) adjustment in the exercise price of outstanding
Stock Options or SARs or the price of Stock Awards or Stock Unit Awards under the Plan; (d) adjustments to any of the shares limitations
set forth in Section 4.1 or 4.2 of the Plan; and (e) any other changes that the Committee determines to be equitable under the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 5.</span></td>
    <td><span style="font-size: 10pt">Grants of Stock Options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1 <span style="text-decoration: underline">Grant</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the Plan,
the Committee may from time to time grant Stock Options to Participants. Unless otherwise expressly provided at the time of the grant,
Stock Options granted under the Plan to Key Employees will be NSOs. Stock Options granted under the Plan to Directors or Consultants who,
in each case are not employees of the Company or any Subsidiary will be NSOs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">5.2 <span style="text-decoration: underline">Stock Option Agreement</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The grant of each Stock Option
shall be evidenced by a written Stock Option Agreement specifying the type of Stock Option granted, the exercise period, the exercise
price, the terms for payment of the exercise price, the expiration date of the Stock Option, the number of shares of Common Stock to be
subject to each Stock Option and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent
with the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">5.3 <span style="text-decoration: underline">Exercise Price and Exercise
Period</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to each Stock Option
granted to a Participant:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The per share exercise
price of each Stock Option shall be not less than the Fair Market Value of the Common Stock subject to the Stock Option on the date on
which the Stock Option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) Each Stock Option
shall become vest and exercisable as provided in the Stock Option Agreement; provided that the Committee shall have the discretion to
accelerate the date as of which any Stock Option shall become exercisable in the event of the Participant&#8217;s termination of employment
with the Company, or service on the Board or as a Consultant, without cause (as determined by the Board in its sole discretion).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) No dividends or dividend
equivalents shall be paid with respect to any shares subject to a Stock Option prior to the exercise of the Stock Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) Each Stock Option
shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, on the date ten years after the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4 <span style="text-decoration: underline">Required Terms and
Conditions of ISOs</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the foregoing,
each ISO granted to a Key Employee shall be subject to the following specific rules:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The aggregate Fair
Market Value (determined with respect to each ISO at the time such Option is granted) of the shares of Common Stock with respect to which
ISOs are exercisable for the first time by a Key Employee during any calendar year (under all incentive stock option plans of the Company
and its Subsidiaries) shall not exceed $100,000. If the aggregate Fair Market Value (determined at the time of grant) of the Common Stock
subject to an ISO which first becomes exercisable in any calendar year exceeds the limitation of this Section 5.4(a), so much of the ISO
that does not exceed the applicable dollar limit shall be an ISO and the remainder shall be a NSO; but in all other respects, the original
Stock Option Agreement shall remain in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) Notwithstanding anything
herein to the contrary, if an ISO is granted to a Key Employee who owns stock possessing more than 10% of the total combined voting power
of all classes of stock of the Company (or its parent or subsidiaries within the meaning of Section 422(b)(6) of the Code): (i) the purchase
price of each share of Common Stock subject to the ISO shall be not less than 110% of the Fair Market Value of the Common Stock on the
date the ISO is granted; and (ii) the ISO shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, no
later than the fifth anniversary of the date the ISO was granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) No ISOs shall be
granted under the Plan after ten years from the earlier of the date the Plan is adopted or approved by stockholders of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5 <span style="text-decoration: underline">Exercise of Stock
Options</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) A Participant entitled
to exercise a Stock Option may do so by delivering written notice to that effect specifying the number of shares of Common Stock with
respect to which the Stock Option is being exercised and any other information the Committee may prescribe. All notices or requests provided
for herein shall be delivered to the Chief Financial Officer of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The Committee in
its sole discretion may make available one or more of the following alternatives for the payment of the Stock Option exercise price: (i)
in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice together with irrevocable
instructions to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject to the Stock Option to
pay the exercise price; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise issuable in connection
with the exercise of the Stock Option having an aggregate Fair Market Value equal to the exercise price; (iv) by delivering previously
acquired shares of Common Stock that are acceptable to the Committee and that have an aggregate Fair Market Value on the date of exercise
equal to the Stock Option exercise price; (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock;
or (vi) by combination of any of the foregoing methods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee shall have the sole
discretion to establish the terms and conditions applicable to any alternative made available for payment of the Stock Option exercise
price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 6.</span></td>
    <td><span style="font-size: 10pt">Stock Awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1 <span style="text-decoration: underline">Grant</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee may, in its discretion,
(a) grant shares of Common Stock under the Plan to any Participant without consideration from such Participant or (b) sell shares of Common
Stock under the Plan to any Participant for such amount of cash, Common Stock or other consideration as the Committee deems appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">6.2 <span style="text-decoration: underline">Stock Award Agreement</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each share of Common Stock granted
or sold hereunder shall be subject to such restrictions, conditions and other terms as the Board may determine at the time of grant or
sale, the general provisions of the Plan, the restrictions, terms and conditions of the related Stock Award Agreement, and the following
specific rules:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Award Agreement
shall specify whether the shares of Common Stock are granted or sold to the Participant and such other provisions, not inconsistent with
the terms and conditions of the Plan, as the Committee shall determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The restrictions
to which the shares of Common Stock awarded hereunder are subject shall lapse as provided in Stock Award Agreement; provided that the
Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant
in the event of the Participant&#8217;s termination of employment with the Company, or service on the Board or as a Consultant, without
cause (as determined by the Committee in its sole discretion).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) Except as provided
in this subsection (c) and unless otherwise set forth in the related Stock Award Agreement, the Participant receiving a grant of or
purchasing Common Stock pursuant to an Award Agreement shall thereupon be a stockholder with respect to such shares and shall have the
rights of a stockholder with respect to such shares, including the right to vote such shares and to receive dividends and other distributions
paid with respect to such shares; provided that any dividends or other distributions payable with respect to the Stock Award shall be
accumulated and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with
the terms of the applicable Stock Award Agreement. Any such dividends or other distributions held by the Company attributable to the portion
of a Stock Award that is forfeited shall also be forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 7.</span></td>
    <td><span style="font-size: 10pt">Stock Unit Awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.1 <span style="text-decoration: underline">Grant</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee may, in its discretion,
grant Stock Unit Awards to any Participant. Each Stock Unit subject to the Award shall entitle the Participant to receive, on the date
or the occurrence of an event (including the attainment of performance goals) as described in the Stock Unit Award Agreement, a share
of Common Stock or cash equal to the Fair Market Value of a share of Common Stock on such date or the date of such event as provided in
the Stock Unit Award Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">7.2 <span style="text-decoration: underline">Stock Unit Agreement</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each Stock Unit Award shall be
subject to such restrictions, conditions and other terms as the Committee may determine at the time of grant, the general provisions of
the Plan, the restrictions, terms and conditions of the related Stock Unit Award Agreement and the following specific rules:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Stock Unit Agreement
shall specify such provisions, not inconsistent with the terms and conditions of the Plan, as the Committee shall determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The restrictions
to which the shares of Stock Units awarded hereunder are subject shall lapse as provided in Stock Unit Agreement; provided that the Committee
shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant in
the event of the Participant&#8217;s termination of employment with the Company, or service on the Board or as a Consultant, without cause
(as determined by the Board in its sole discretion).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) Except as provided
in this subsection (c) and unless otherwise set forth in the Stock Unit Agreement, the Participant receiving a Stock Unit Award shall
have no rights of a stockholder, including voting or dividends or other distributions rights, with respect to any Stock Units prior to
the date they are settled in shares of Common Stock; provided that a Stock Unit Award Agreement may provide that until the Stock Units
are settled in shares or cash, the Participant shall be entitled to receive on each dividend or distribution payment date applicable to
the Common Stock an amount equal to the dividends or other distributions that the Participant would have received had the Stock Units
held by the Participant as of the related record date been actual shares of Common Stock. Such amounts shall be accumulated and held by
the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms of the applicable
Stock Unit Award Agreement. Such amounts held by the Company attributable to the portion of the Stock Unit Award that is forfeited shall
also be forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 8.</span></td>
    <td><span style="font-size: 10pt">SARs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1 <span style="text-decoration: underline">Grant</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee may grant SARs to
Participants. Upon exercise, an SAR entitles the Participant to receive from the Company the number of shares of Common Stock having an
aggregate Fair Market Value equal to the excess of the Fair Market Value of one share as of the date on which the SAR is exercised over
the exercise price, multiplied by the number of shares with respect to which the SAR is being exercised. The Committee, in its discretion,
shall be entitled to cause the Company to elect to settle any part or all of its obligations arising out of the exercise of an SAR by
the payment of cash in lieu of all or part of the shares it would otherwise be obligated to deliver in an amount equal to the Fair Market
Value of such shares on the date of exercise. Cash shall be delivered in lieu of any fractional shares. The terms and conditions of any
such Award shall be determined at the time of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">8.2 <span style="text-decoration: underline">SAR Agreement</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) Each SAR shall be
evidenced by a written SAR Agreement specifying the terms and conditions of the SAR as the Committee may determine, including the SAR
exercise price, expiration date of the SAR, the number of shares of Common Stock to which the SAR pertains, the form of settlement and
such other terms and conditions established by the Committee, in its sole discretion, not inconsistent with the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The per Share exercise
price of each SAR shall not be less than 100% of the Fair Market Value of a Share on the date the SAR is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) Each SAR shall expire
and all rights thereunder shall cease on the date fixed by the Committee in the related SAR Agreement, which shall not be later than the
ten years after the date of grant; provided however, if a Participant is unable to exercise an SAR because trading in the Common Stock
is prohibited by law or the Company&#8217;s insider-trading policy, the SAR exercise date shall be extended to the date that is 30 days
after the expiration of the trading prohibition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) Each SAR shall become
exercisable as provided in the related SAR Agreement; provided that notwithstanding any other Plan provision, the Committee shall have
the discretion to accelerate the date as of which any SAR shall become exercisable in the event of the Participant&#8217;s termination
of employment, or service on the Board or as a Consultant, without cause (as determined by the Committee in its sole discretion).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e) No dividends or dividend
equivalents shall be paid with respect to any SAR prior to the exercise of the SAR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f) A person entitled
to exercise an SAR may do so by delivery of a written notice in accordance with procedures established by the Committee specifying the
number of shares of Common Stock with respect to which the SAR is being exercised and any other information the Committee may prescribe.
As soon as reasonably practicable after the exercise of an SAR, the Company shall (i) issue the total number of full shares of Common
Stock to which the Participant is entitled and cash in an amount equal to the Fair Market Value, as of the date of exercise, of any resulting
fractional share, and (ii) if the Committee causes the Company to elect to settle all or part of its obligations arising out of the exercise
of the SAR in cash, deliver to the Participant an amount in cash equal to the Fair Market Value, as of the date of exercise, of the shares
it would otherwise be obligated to deliver.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 9.</span></td>
    <td><span style="font-size: 10pt">Change in Control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1 <span style="text-decoration: underline">Effect of a Change in
Control</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) Notwithstanding any
of the provisions of the Plan or any outstanding Award Agreement, upon a Change in Control of the Company (as defined in Section 9.2),
the Board is authorized and has sole discretion to provide that (i) all outstanding Awards shall become fully exercisable, (ii) all restrictions
applicable to all Awards shall terminate or lapse and (iii) performance goals applicable to any Awards shall be deemed satisfied at the
highest level, as applicable, in order that Participants may realize the benefits thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) In addition
to the Board&#8217;s authority set forth in Section 3, upon such Change in Control of the Company, the Board is authorized and has sole
discretion as to any Award, either at the time such Award is granted hereunder or any time thereafter, to take any one or more of the
following actions: (i) provide for the purchase of any outstanding Stock Option or SAR, for an amount of cash equal to the difference
between the exercise price and the then Fair Market Value of the Common Stock covered thereby had such Stock Option or SAR been currently
exercisable; (ii) make such adjustment to any such Award then outstanding as the Board deems appropriate to reflect such Change in Control;
and (iii) cause any such Award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.
Without limiting the generality of the foregoing, in the case of any Stock Option or SAR with an exercise price that equals or exceeds
the fair market value of the per share consideration received by holders of Common Stock in the Change in Control, the Board may cancel
the Stock Option or SAR without the payment of consideration therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2 <span style="text-decoration: underline">Definition of Change
in Control</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Change in Control&#8221;
of the Company shall be deemed to have occurred if at any time during the term of an Award granted under the Plan any of the following
events occurs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) any Person (other
than the Company, a trustee or other fiduciary holding securities under an employee benefit plan of the Company, or a corporation owned
directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of shares of Common
Stock of the Company) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 30% or more
of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of directors
(&#8220;Person&#8221; and &#8220;Beneficial Owner&#8221; being defined in Rule 13d-3 of the General Rules and Regulations of the Exchange
Act);</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) the Company is party
to a merger, consolidation, reorganization or other similar transaction with another corporation or other Person unless, following such
transaction, more than 50% of the combined voting power of the outstanding securities of the surviving, resulting or acquiring corporation
or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions) is then
beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners
of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors immediately prior to such transaction,
in substantially the same proportions as their ownership, immediately prior to such transaction, of the Company&#8217;s outstanding securities
entitled to vote generally in the election of directors;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) the election to the
Board, without the recommendation or approval of two-thirds of the incumbent Board, of the lesser of: (i) three Directors; or (ii) Directors
constituting a majority of the number of Directors of the Company then in office; provided, however, that Directors whose initial assumption
of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating
to the election of Directors of the Company will not be considered as incumbent members of the Board for purposes of this Section; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) there is a complete
liquidation or dissolution of the Company, or the Company sells all or substantially all of its business and/or assets to another corporation
or other Person unless, following such sale, more than 50% of the combined voting power of the outstanding securities of the acquiring
corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions)
is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial
owners of the Company&#8217;s outstanding securities entitled to vote generally in the election of directors immediately prior to such
sale, in substantially the same proportions as their ownership, immediately prior to such sale, of the Company&#8217;s outstanding securities
entitled to vote generally in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In no event, however, shall a
Change in Control be deemed to have occurred, with respect to a Participant, if that Participant is part of a purchasing group which consummates
the Change in Control transaction. A Participant shall be deemed &#8220;part of a purchasing group&#8221; for purposes of the preceding
sentence if the Participant is an equity participant or has agreed to become an equity participant in the purchasing company or group
(except for (a) passive ownership of less than 3% of the shares of the purchasing company; or (b) ownership of equity participation in
the purchasing company or group which is otherwise not deemed to be significant, as determined prior to the Change in Control by a majority
of the disinterested Directors).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 10.</span></td>
    <td><span style="font-size: 10pt">Payment of Taxes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) In connection with
any Award, and as a condition to the issuance or delivery of any shares of Common Stock to the Participant in connection therewith, the
Company shall require the Participant to pay the Company the minimum amount of federal, state, local or foreign taxes required to be withheld,
and in the Company&#8217;s sole discretion, the Company may permit the Participant to pay the Company up to the maximum individual statutory
rate of applicable withholding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The Company in its
sole discretion may make available one or more of the following alternatives for the payment of such taxes: (i) in cash; (ii) in cash
received from a broker-dealer to whom the Participant has submitted notice together with irrevocable instructions to deliver promptly
to the Company the amount of sales proceeds from the sale of the shares subject to the Award to pay the withholding taxes; (iii) by directing
the Company to withhold such number of shares of Common Stock otherwise issuable in connection with the Award having an aggregate Fair
Market Value equal to the minimum amount of tax required to be withheld; (iv) by delivering previously acquired shares of Common Stock
of the Company that are acceptable to the Board that have an aggregate Fair Market Value equal to the amount required to be withheld;
or (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Committee shall have the sole discretion to establish
the terms and conditions applicable to any alternative made available for payment of the required withholding taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 11.</span></td>
    <td><span style="font-size: 10pt">Postponement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee may postpone any
grant or settlement of an Award or exercise of a Stock Option or SAR for such time as the Board in its sole discretion may deem necessary
in order to permit the Company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) to effect, amend
or maintain any necessary registration of the Plan or the shares of Common Stock issuable pursuant to an Award, including upon the exercise
of a Stock Option or SAR, under the Securities Act of 1933, as amended, or the securities laws of any applicable jurisdiction;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) to permit any action
to be taken in order to (i) list such shares of Common Stock on a stock exchange if shares of Common Stock are then listed on such exchange
or (ii) comply with restrictions or regulations incident to the maintenance of a public market for its shares of Common Stock, including
any rules or regulations of any stock exchange on which the shares of Common Stock are listed; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) to determine that
such shares of Common Stock and the Plan are exempt from such registration or that no action of the kind referred to in (b)(ii) above
needs to be taken; and the Company shall not be obligated by virtue of any terms and conditions of any Award or any provision of the Plan
to sell or issue shares of Common Stock in violation of the Securities Act of 1933 or the law of any government having jurisdiction thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any such postponement shall not extend the term of
an Award and neither the Company nor its Directors or officers shall have any obligation or liability to a Participant, the Participant&#8217;s
successor or any other person with respect to any shares of Common Stock as to which the Award shall lapse because of such postponement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 12.</span></td>
    <td><span style="font-size: 10pt">Nontransferability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Awards granted under the Plan, and any rights and
privileges pertaining thereto, may not be transferred, assigned, pledged or hypothecated in any manner, or be subject to execution, attachment
or similar process, by operation of law or otherwise, other than by will or by the laws of descent and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 13.</span></td>
    <td><span style="font-size: 10pt">Delivery of Shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of Common Stock issued pursuant to a Stock
Award, the exercise of a Stock or SAR or the settlement of a Stock Unit Award shall be represented by stock certificates or on a non-certificated
basis, with the ownership of such shares by the Participant evidenced solely by book entry in the records of the Company&#8217;s transfer
agent; provided, however, that upon the written request of the Participant, the Company shall issue, in the name of the Participant, stock
certificates representing such shares of Common Stock.&#160; Notwithstanding the foregoing, shares granted pursuant to a Stock Award shall
be held by the Secretary of the Company until such time as the shares are forfeited or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 14.</span></td>
    <td><span style="font-size: 10pt">Termination or Amendment of Plan and Award Agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.1 <span style="text-decoration: underline">Termination or
Amendment of Plan</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) Except as described
in Section 14.3 below, the Board may terminate, suspend, or amend the Plan, in whole or in part, from time to time, without the approval
of the stockholders of the Company, unless such approval is required by applicable law, regulation or rule of any stock exchange on which
the shares of Common Stock are listed. No amendment or termination of the Plan shall adversely affect the right of any Participant under
any outstanding Award in any material way without the written consent of the Participant, unless such amendment or termination is required
by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed. Subject to the foregoing,
the Committee may correct any defect or supply an omission or reconcile any inconsistency in the Plan or in any Award granted hereunder
in the manner and to the extent it shall deem desirable, in its sole discretion, to effectuate the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The Board shall have
the authority to amend the Plan to the extent necessary or appropriate to comply with applicable law, regulation or accounting rules in
order to permit Participants who are located outside of the United States to participate in the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.2 <span style="text-decoration: underline">Amendment of Award
Agreements</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee shall have the authority
to amend any Award Agreement at any time; provided however, that no such amendment shall adversely affect the right of any Participant
under any outstanding Award Agreement in any material way without the written consent of the Participant, unless such amendment is required
by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">14.3 <span style="text-decoration: underline">No Repricing of Stock
Options</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
and except as described in Section 4.3, there shall be no amendment to the Plan or any outstanding Stock Option Agreement or SAR Agreement
that results in the repricing of Stock Options or SARs without stockholder approval. For this purpose, repricing includes (i) a reduction
in the exercise price of the Stock Option or SARs or (ii) the cancellation of a Stock Option in exchange for cash, Stock Options or SARs
with an exercise price less than the exercise price of the cancelled Options or SARs, other Awards or any other consideration provided
by the Company, but does not include any adjustment described in Section 4.3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 15.</span></td>
    <td><span style="font-size: 10pt">No Contract of Employment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither the adoption of the Plan
nor the grant of any Award under the Plan shall be deemed to obligate the Company or any Subsidiary to continue the employment or service
of any Participant for any particular period, nor shall the granting of an Award constitute a request or consent to postpone the retirement
date of any Participant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 16.</span></td>
    <td><span style="font-size: 10pt">Applicable Law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All questions pertaining to the
validity, construction and administration of the Plan and all Awards granted under the Plan shall be determined in conformity with the
laws of the State of Nevada, without regard to the conflict of law provisions of any state, and, in the case of Incentive Stock Options,
Section 422 of the Code and regulations issued thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 96px"><span style="font-size: 10pt">Section 17.</span></td>
    <td><span style="font-size: 10pt">Effective Date and Term of Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.1 <span style="text-decoration: underline">Effective
Date</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The Plan was initially
approved by the stockholders of the Company on April 6, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The Plan as
amended and restated has been adopted by the Board, and is effective, as of November 17, 2025, subject to the approval of the Plan by
the stockholders of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) In the event
the Plan is not approved by stockholders of the Company within 12 months of the date hereof, the Plan as amended and restated shall have
no effect, and the Plan as in effect prior to November 17, 2025 shall continue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2 <span style="text-decoration: underline">Term of Plan</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary contained herein, no Awards shall be granted on or after April 6, 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CNS PHARMACEUTICALS,&#160;INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD
ON</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 17, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned stockholder acknowledges receipt
of the Notice of Annual Meeting of Stockholders and the Proxy Statement, each dated October 24, 2025, and hereby appoints John Climaco
and Christopher Downs, or either of them, proxies for the undersigned, each with full power of substitution, to vote all of the undersigned&#8217;s
shares of common stock of CNS Pharmaceuticals,&#160;Inc. (the &#8220;Company&#8221;) at the Annual Meeting of Stockholders of the Company
to be held virtually at https://westcoaststocktransfer.com/proxy-CNSP/, on November 17, 2025 at 12:00 P.M. Eastern Standard Time, and
at any adjournments or postponements thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 8pt">1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td colspan="4" style="vertical-align: top"><span style="font-size: 8pt">For All</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td rowspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 8pt">The Board of Directors has nominated
    the following six persons for election as directors of the Company: John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith
    Charles, Bettina Cockroft and Amy Mahery. Their term will expire at the 2026 Annual Meeting of Stockholders, or until their successors
    are duly elected and qualified.</span></td></tr>
  <tr>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td colspan="4" style="vertical-align: top"><span style="font-size: 8pt">Withhold All</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td colspan="4" style="vertical-align: top"><span style="font-size: 8pt">For All Except</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="3" style="vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 2%; text-align: center"><span style="font-size: 8pt">2.</span></td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="vertical-align: top; width: 3%"><span style="font-size: 8pt">For</span></td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="vertical-align: top; width: 5%"><span style="font-size: 8pt">Against</span></td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="vertical-align: top; width: 5%"><span style="font-size: 8pt">Abstain</span></td>
    <td style="width: 79%; text-align: justify"><span style="font-size: 8pt">To ratify the appointment of MaloneBailey, LLP as the Company&#8217;s
    independent registered public accounting firm for the year ending December 31, 2025.</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 8pt">3.</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">For</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">Against</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Abstain</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">To vote on a non-binding, advisory resolution to approve executive compensation.</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 8pt">4.</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">For</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">Against</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Abstain</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">To vote on a non-binding, advisory proposal on the frequency of holding
    future votes regarding executive compensation.</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 8pt">5.</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">For</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">Against</span></td>
    <td style="text-align: center"><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Abstain</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">To approve an amendment to the Company&#8217;s Amended and Restated
    Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares to 300,000,000
    shares and the total number of authorized shares of preferred stock from 416,667 shares to 5,000,000 shares.</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">6.</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">For</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Against</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Abstain</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">To approve amendments to the Company&#8217;s 2020 Stock Plan including
    an increase in the number of shares of common stock authorized for issuance under the Company&#8217;s 2020 Stock Plan.</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 8pt">7.</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">For</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Against</span></td>
    <td><span style="font-family: Wingdings; font-size: 8pt">o</span></td>
    <td><span style="font-size: 8pt">Abstain</span></td>
    <td style="text-align: justify"><span style="font-size: 8pt">To authorize the adjournment of the Annual Meeting, if necessary, to
    solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof
    to approve the above proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE: In their discretion, upon such other matters as may properly come
before the meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The board of directors recommends a vote FOR the nominees and proposals
above and if no specification is made, the shares will be voted for such nominees and proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 53%">&#160;</td>
    <td style="width: 47%"><span style="font-size: 10pt">Dated _______________________________________ 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Stockholder&#8217;s Signature</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Stockholder&#8217;s Signature</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Signature should agree with name printed hereon. If
stock is held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys
should indicate the capacity in which they sign. Attorneys should submit powers of attorney.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE
ENCLOSED. THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL
BE VOTED FOR THE NOMINEES SET FORTH IN PROPOSAL 1, AND FOR THE PROPOSALS SET FORTH IN ITEMS 2-7. THIS PROXY WILL REVOKE ALL PRIOR PROXIES
SIGNED BY YOU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Important Notice Regarding the Availability of Proxy
Materials</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">for the Annual Stockholder Meeting to be Held on November
17, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Electronic Copies of the Proxy Statement and our 2024
Annual Report on Form&#160;10-K are available at</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">http://icomproxy.com/cnsp</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 55; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi9aCLrrToiJWkVLE7WijDLaTkhm1PZK3NG0RQyB/73tRaqQ2tDYlMpyXWQo5VnWpPUKGN2S0VxRFst3FIDXDu3GetfX9+AMTEgaFmY+ji+x75cs4LGKYhhPJaCZNPAthsVdBd0/I3kyB1htdgrYFHJlqNug1t4NDrhuyVLX9pxOyM2TFbhwO5w9E4TSCA730m/jhIE0TFYz6CNSG6VmLatV4tB0JqxIreecG+p/BF7w+SkI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>cnsp-20251117.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaKJWaPty5522YkxvmR8fSlavygrCHlg0iIvrRW24VEK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:CNSP="http://cnspharma.com/20251117" elementFormDefault="qualified" targetNamespace="http://cnspharma.com/20251117">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cnspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20251117_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20251117_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20251117_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>cnsp-20251117_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cnsp-20251117.xsd#Cover" roleURI="http://cnspharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cnspharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cnsp-20251117_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="ecd_RecoveryOfErrCompDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="ecd_RecoveryOfErrCompDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RecoveryOfErrCompDisclosureLineItems_lbl" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_2_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_2_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_MnpiDiscTimedForCompValFlag_2_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_2_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cnsp-20251117_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cnsp-20251117.xsd#Cover" roleURI="http://cnspharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cnspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CNS
    Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001729427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_RecoveryOfErrCompDisclosureLineItems', window );"><strong>Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">We do <span id="xdx_908_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20251117__20251117_zFNJUWyRfjO">no</span>t grant equity awards in anticipation of the
release of material nonpublic information, and do not time the public release of such information based on award grant dates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_RecoveryOfErrCompDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_RecoveryOfErrCompDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th"><div>Nov. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text">We do <span id="xdx_908_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20251117__20251117_zFNJUWyRfjO">no</span>t grant equity awards in anticipation of the
release of material nonpublic information, and do not time the public release of such information based on award grant dates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th"><div>Nov. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>8</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cns_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cnspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cns_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cns_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="cns_def14a.htm">cns_def14a.htm</File>
    <File>cnsp-20251117.xsd</File>
    <File>cnsp-20251117_def.xml</File>
    <File>cnsp-20251117_lab.xml</File>
    <File>cnsp-20251117_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cns_def14a.htm": {
   "nsprefix": "CNSP",
   "nsuri": "http://cnspharma.com/20251117",
   "dts": {
    "inline": {
     "local": [
      "cns_def14a.htm"
     ]
    },
    "schema": {
     "local": [
      "cnsp-20251117.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cnsp-20251117_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cnsp-20251117_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnsp-20251117_pre.xml"
     ]
    }
   },
   "keyStandard": 8,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 150,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://cnspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_def14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_def14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_def14a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_def14a.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r29",
      "r39",
      "r65"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r32",
      "r42",
      "r68"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r61",
      "r69",
      "r73",
      "r81"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r79"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "verboseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://cnspharma.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "verboseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r25"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r29",
      "r39",
      "r65"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r26",
      "r36",
      "r62"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r69"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r69"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r69"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r69"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r69"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r61",
      "r69",
      "r73",
      "r81"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "verboseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "verboseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r31",
      "r41",
      "r67"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r44",
      "r70"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r44",
      "r70"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r26",
      "r36",
      "r62"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r27",
      "r37",
      "r63"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r28",
      "r38",
      "r64"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r45",
      "r71"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r30",
      "r40",
      "r66"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-25-007760-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-007760-xbrl.zip
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MU]]X_W>0"#M$L2OL@5P-,K?KW[HH?\6!L./8\7L6@J+N^PG:FAV'K+8 C%F
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M!&XMSMBR<..Q<HYMXP+>">GWVD8_,B]J6OC7TZ"\9T"Y]A:UKRNXPA_^9JO
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M)JV2:$;_*5,KG6KUG36;A<9]CU8Z#CJ0XXA_!U0I!^N$ 'C;SBCFN(-:I7J
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M 'Q=&;3)XNT9C)MX=BCJ]/C8"!(@ZW46,4OHZF(\N9(A45A-/@D)OTJ4P&+
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M8(-;_TL<'%1J!V7LK].-P\#']C1:$(ER5R>_#"IP@/H<QGQ2^KBSRM$TUU-
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M!0Z]0*;V5-7J@9U93A+X R]Y%9;;F\UR\ _@CX K>!S^&O=?]K(Y'<RSZA9
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MD>RR1.S@N3SX"SB@&PA21P25"-W\9-U!6?Y$MD#^'+4JAW<&ZRQ_#NW#%LC
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M!FSM=]2 %N38Z??>$)'!Z''XNO5^;]^C_KY<?^=N6:U/[8>EK&7;<TR:O!1
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M&'%3+= &R*[\\_2CQU2H\)^R& S$1 T3 H%.SJ_=RX((A>F=1;V=DCEA,YO
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M265=C7"=ZO4U)9*=<MD]>FO(WJ"6(BCIV(U_+7\=[VUUBSY[T;7W=O&VJ'/
MZ&!$@Y*(:>M.678^I!?4 .AX[N-N?%.I/<-KC8E@<F\:-P-5)U<]"OJ:@7ND
M[%YXA-O9>6:=8#YOE>>HP!FK.O,J<+,@N$JZ!Z<4F=L[-7J!5DN<6LZJ=7"*
M>EIP[I3J4(I<K5A^AK/0T@A4,Q6M$V!FW0!.BZ>U#M7M3B]CR[*:_8*GJU:A
M:';QFTH*9Z:6L:W=0Q9DB,DILU["I>\$AZ"+-'AIJ@()Z\ZX[Z6)W A/4)8E
MV?BZZDJ;!LO*9%;2<TE1]-?#.M.V]1/<^IKS[=2_&B2DJFN/#D/#XUXE+/2
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MQ7CYGB$T*0@.AZETBK T4T*+U+H@4D$86.S+U;RPYB)&,?C*UTL:9*D@#5A
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MXD&](HF'Z_L$%S/B%OQ-'[[98L/ETTIE#Z"LJ7+.^4[+.C#$3[_]-1@,DJF
M0FR=#/TPV5[*P)]\))6 4BQEQ,YX*G 5JQ6MW@RUY"8E[S<NG5=PZ1QL7#JO
M?RQ>P%'3-HZ:/SMGGSL?SCZ?W?S#O?BDTH+87^->G&,,XPO=EV_!>=.!TSN9
MJH0)O-EG*0A#/W4H4CE&I8]:TL.%GW"C$M$".#ST?6K4DA(B5%I R#<19]*/
M8XX3U<:'2ZWPG'LQK3&LH[0>SC_Y/@R[H4F U@L@2Y8"6S(2KCX,E$J=6C]5
MMFPO3C.N/4 =/,#^F%,W "J2;\->UHYSQ4\P)I49F5(*],#ID'(="#<C%"*<
MG%^[EZ 4C/U>D)-@3#W>_;.HMP,:%TA4F#J\_',<3]QKF-@0MC@'1=!]O[OK
MN7_$L*'HM[KY'^?H:+=]Y+F=3.)[OX#ZE<!>8LL34-"2(/.3YV\_N7;C-XJ&
M/2T:+F[^.+UR.5_Q]*/;.<$TPK<@!2YT=EW!!M$=N-'5PJ>SF[ /;^H(E)]8
MVU;/X_*AC;"O*XX$5M&W*+[GLS[5/^5<"!YN A^@855^8>/PI=[,Q4E1\W ^
M!%SQ7"N=,-0;)",J+ QF+82<Q#+!"!2%OLIW0P\H&5G8<P3]G"J+2YJ"D$BC
M,#2W3^8VL%0[H4VG9&8FA-F4%6L"\O+'<5\?QS\NOEZ?_G'Q^>/9^>]X4\/!
M_)]_N%\Z-Z=79YW/UV_A8&(DX_KTA-I5^OUX@H9_DH\"\0],$*(I<YG[Q.IV
MR"\*W!GZ"2$8!#NW<(5P?D>Z39<Q\%@Z8 3(/MQE<'2F11<3^>R)@>$LP50Q
MPZ[2O^8^UBFGA>L=RX>H^P[F-E(KCGX_P:RG[E2]3A((L1-R4#F0\KARE\1I
MZ9[E_JHZD,+R(TRE6&F$2QD$B:2H@<8B(%%P[Z:!] #R! ?*G<1T2U(#'\R$
M1%=TEOB2/!V2LH_$*&:@1GW6"U+_#I,LY;Z735CCJY4(BVX?#SM:ZU0BX1UQ
M]+/S5*75.M@BT!>)6?8U%:B&V7"@]=3LAMH,D[.KN0X;, N;*$55LI\*O EC
M@V*JN(MW?IR/LG RJF=."D,)6^8190%2&(%[,:59DO<LT$_2>;6#ESRW)/<I
M*TJU^]9JX 4RS33.5>!'?B::+OUZBDN5E"OEZ3,=I&S:E+VWL##ZL4S>*SY,
M(^!"PBA')##L+H@SD>PG;DY.E^0]5=$FKGDF">Y@/CPZ#(%A&TS ]ES)XL6T
M3(^>C#C/$N8.HPQQ2KI+54;9^_:<R'U\3SKOA ZFF^F>DB@#..@Z<WM!\1]1
MI2)",-,RIC8%J5T>HN0R4BU_I3SPHK4[2]:RW?FT;*XS5KP'1\4Q]I*B@>;3
M@BU287%FDE#OO&OH.D(\6J(J6R@%EE"QO!(C.6*'(+-@>BH_(R<=]MWN\DSF
M3XF@NF>;S"8-,D%>8U>X[A@(ZQA/LI$6_>4]=QK6*\T1"U#"F/]-Q:E]_5Z=
M'>S7R8E^W,OY1D,H6BT>UEA$;\9_Y33F!SVU^[L;3^TK>&H/-Y[:=3I +V I
M'FA+\?KFXN1O:"EJ]PW8AV[G_*-[_?7#E[/KZ[.+\S=A+YY9E9/8BE3Y*0FO
M 5VD5-"&]95*U78LNXOS+RSO!;5L8+_P8<4=XIL:!--"EF_J2H5;WI7X;^51
MT.<099C3\'3+<*DGJKH_/%"7THR[OHI>#5H!KP;>"1KH"$%BI)=$3+TD4M!6
M$7&4_#5&APN^^RFILGZFRI2PNX'3;GN\X"V<NI@K'P._/X)YBJFRO8-.95)0
M3"'&D/43:VVH'G,U'#\5B*4886_$1)(+,P6=42:Q@_6YV@>G5&W5_T!\3V6U
MB6/X?F8*D9 X'<D_X)H;VO*^^V$Z\N]UH@Q:?(7J+[4PAWG)V%8X&VF4#C1K
MM:6:"C8@3K1:&$7X-)6=R7CH[D:&4+VW:ZP]U\K%[ 4"5$(DD=6@LECV!00-
M\W9AP)C9!6US$Z'@?$A.9BSY/,A5S\/9*JT<&(N*3HF*:ZQ1_GT8D->4^GZ0
M]00G2#EYNH%*X2O&9$PUCIAF*0S*P$M!I@H,X0(>Q:D4D$ZU);#C_@.I25[1
M,'7#,0::5 ]V9:T6#Q)LK53F49ENQM[A8>#4%/&J@\+C1^*R9<L5?1#(!?W$
MOV<[D:=FF;A%/L9!7FIO5QHGK D06D8_1&#-9?23^C!U+Q+9\GH/^'(P2G_Z
MC=P!?W2NOG1.3K_>G)V 2J#< ><G.Q6,TK+V>/Q(',2?YD;0>\R0#^!OV]\2
M0_;Q5/GLP" <)[SD?OKM+^E?W+]>_''NGGP^ _I<:(BT.;'XEC9CNZOPR[]]
M@<[%SPE)^)SU,$5]:)DCJP9"F"R('8266L7S;.5!FX%?8N#Y2QGW6QMORBMX
M4XXVWI35/C+/X*(H.$\.34+<^?GI_[B=9WOO,R<0G)Q>W9Q] O7NYI32^;Z<
MGG^$_W_S;"^\N6 X,7P19@F=?W2O3J]OX/WP!\SEY//I-<X$M,R+J\N+*P(C
M<RX^/1\%:A1=5^FXZ^OMD@]#JDN$AW8.PD@66PKRN1S?PZ@^A^BP*5"<W/H1
M@9FBT1A\#U.R( V8*3E'Q JYSL1I<1[<^7V_X!JR@M[H&3(^C#PAEP]ZO-!Q
M0(4U65KKBW$Z>"^,./H'LS7SK,L7.AGZ$_19'1VK^<FTKH*[,*5VNWZ69TA)
M<A]AYE$7W2S? EDL*K2"H'6"5]( PX(!>E<Z"CY66<"UKJ/&Z7I8WN7S3[BB
MRYY!C]XU)0?5+R_+%\_K1:E_9XO=4Y1KR@5#VD5%+A7G6MR=>SLM#7:R$+E-
M9:/YB+PGIB.LYCUVSN"(^)?U:L=/I9-6NJZ; H\N\MZ;$LG2H:_ ;LAYR8@T
M&2%F43<GV,<D"-P_0#J@!_1+.!KA[[;V=G>]7?[_VTVPR4-*$D)WN9^X6-7*
M76.Q47'+U1U1RR(%?N]0\H#V.+\\F5YK>]KSGYOV2Y\;KH]+,/D++SMLN =C
M61.2>NA((<VIKF#4)5%DJD+N<\GEW$U)O38CZCI]:_G6&Y9Q2->$$Q8_J)_0
M3Z//YT'=Z9SH_,!'']!+-<3RS^B*WVE[?#;1/KN-B6Q*87 P294RY?KY:*K3
M58OZR_G5-:@M.WO'!S\ K?8E55632/@7([.4.@B\ZG Y_/_"?]S)SAC4U%,?
M\34B>C_"FM)W__L#D.OLW/W[V<WYZ?6U^_<_3J].+SZ!YLY)E!A=@L-65EA9
M@_U?_@]&(14IG]&T*9KXK[8G*QTL*C25*3F*]@_GZF!UL/]@>Z]&4^^_NLE?
M?G/L__XP_46Q2?4__(C=-'[V?[.SK!"96'"$&RQ_^\6=([RPW%#"+,>/'14B
M(%),!?G%S2=P _9\W'.U:<OJA[N9S68V+S^;XCQF11[:F\C#TR(/G7?SQ![^
M1(T;9ER-0K0V08C-.7WU>13"(D<F+!)%P7?WPZI,\V4V[^5#"=12[/2_OR(:
MP^7GSOFSO6BKSH.T#-2?^M<UJ*(O$F1[?MOA*0;"^\/)]X=4?^4-:^W4YN(\
MT$<V10*$Z5!G/5]RJ.89.T'2_[5>+Q#1<F]JD^G0>=EH1\T,<P6*B@*ZT3P*
M'V%NWDMM"'%8596+'Y@QE5=$0 ([DR0<N8>4/[2K*GVQDLMN]OM@X6D]D)I3
MS"Q&1PNF?[O'_#9V<]%T[TU(JSK#_!83C-_3C_8\^?2+G\!$VX<**PUY#,8_
MARE336WKB%.B/"?-N_^45%N-B?_X-;G5-57>N;:9RDVLW>9@@8FV9K)QV, #
MZ9K!C=G+5'*R3\G<IG4LC!?>A?V<:BQ3Q'QS3\>343P-<&8&# -_?A)'"%OJ
M6RB,"E.2,(+AX^N\FX92>X^HIP[F+=]&JKT!%1F'W9R+>>V8P*R!D"7FG9BG
M@'0$XL:AG/:YE\4UWJ:1 O;1B8CAJ='$A-LD]3%K6[=M@G\-0D$[]GO#,)#/
M8^)M^&WJS$6M[E0F32U]%Y\VO7."V>1Y)$$!O\?%#7'BZ'ZG7.J*90+PVHPK
MOA'1F+MLV-/,ADF<WPZYUF1"D,6=>Q"A+Y;N_W9NZO9C;NJ/P2",B!.?LTOS
MZ][-G=3-4X,E@X*+H68X)$] &D$R3JW8%Y?3!'Y$X!.F3*4;P _6-83/_X>#
M-AR,]DY+^5!)<Y@[F9V.K+"/@IH@K ^'1-$]Z40)4"\"=LO<6["O,'!E,H%X
M3UC[T!$<7WJ(7TPD[T7^IK>9/[\"__)G+A6,N=>=JV5(CP?)]1J\W-YI/V&+
MW,YM$E Q5G&S'-HLSBS2D,A>:0/,CSU[(ZH?6QNBO\.M@7VQ/@CPZHQZ@A1"
MCSOUC/'&]*GVSM[CMI!LB[J-:RCC*2E0;XZ,^X\CXPDC)H>1<Q(3K'U)< UU
M<SL2_\4B1779'IN\F#?)H@?NPF2-^T$C<YZI3@)7V $S1Y[LDR71>G]\:&<T
M"O0/K("T=OC?-T?:PT>05I#.&^F+1SR(4D[A,<#HQ0H_*;YE!+^>U4E& 4?U
M \P"H+PNL9#YEY4]X3Z78] <,9'",3=XG'#SN)A?95YB,E?,.\3"I@$%L9 N
M@!3[4X@:(+U3929OCA>.'L4+L,=TT\YB!_V09R5=E3.NO+=^11P_AKZ6$TXH
M+*2=F?DN">)6"N2;H^;[1U!3.1!J>970':1XW.!9$'#<79BB,$'LNQ#QC&_]
MVXHS4O1]?X!=$BA9"1&Z2'?L\8O)19>HX:9PER=WH4K_#%.GI^2F]* EJ:4>
MVG'_4*BG\A%&H /,O(,!M)Y%X&@3?ZH::OKN( @JHWF,U87U_ST?S%%K (%_
M4* 5*!F-2UC13VDGA!O)GKBTH(&XYW&&/AKM=LOL)$("$R%*(SFS)& )C.LP
M[W"4W@V/D%^6L!Y#7!(!/%^_.X8+'+M32;+HM48V,1J[U:&BTZ-68/Z='X[(
MS4+[P]VMW"#,AO*3>#!@= 3&LQP%)6>6<=":L3.Y8GA1:WO47GC\6<D8>YMD
MC*<E8WS8)&.L!+[6NI[5IFNWM;OPO:NNEOI;5V \34=F=9_*;8N7%+PGD+!
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M>(+TS03FGL!]<J*A$X.-\!(P5Z4L=/BU0J0CD0#G)#U56I0! ^4XL& >D/:
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MPB'PHJ%R0?AT2Q7!(!&%+= N0$:*$B/Y528#]Q@D':M A,;LY1](C!0O?IX
M'R#3OAGP%@\"27/"CR%_R]NRB*(K HG%PS..)_K:D/; [5&ZTNPI6\B8%9.G
M>3^.L'?[*1DVDNL"M&!6=99DZ1.EWA(X4A^B(HITW!9*H@1P$(N3+,74+SX2
M*#8*$Z$V\U/-3S\5/;;BZY -T&PR#OX[U;GMW!0)#[K"FZO4UU&2C52E3P72
MI7[M$%!4EIN:TI1AA3S%BPDRH$RN#GB_<<\2Q\7"4,H_!-BA<5Q"@1BQ^@C3
MRA1]Y-Z-N^N@["O*R*&AAAE[21A!9@XX4UH)[.% 5"*:)V$@A(:1&I.(_)TD
M-0T*C)4I4 .LDHV"5H158_DHJN- D#YKN"'P!L>JQ%'P0E,F1!':2=EU2FT\
M"1-RE<IW)7"3,@QMW75CB3P42V1W'DND 7'58)!R.2A.X1K8(_R*4Q5Y<<6&
MKU!@!/ :8!D.D^@ZZH6782JQ#T4="+<;8A_-!B'GY7IA%@3$X"\QUV?8"SN7
MQ.)^-1["?6SC8R"49CX)S-_'!'_3X<;?K_:( D] K-:^0M:@6*=5HP</LJSX
MLQ(/0ZUM"W0TY3CS)18CA/];(AL/^AM+68_W'ZC9))>3R0/QNR[S&EVYO7FN
MW*$1<#TG..QUN'+GY;8>I'68EI[PD ISS[3O3$M?F/C*4K.\!.4T;+K8A30Q
M4L+)^QG!E:2G&4R203QX9ORBPUI!&DE"&DQ(M(IX#*VT@.]$(\."RX%JBEIQ
M_ MR[!*5;D8<**5I>E*VL.#2 LIS\X>582RAM\!;"' 8<2Y#J0A\"C=%U:0/
M@GY8^$5<.F8MG55)5*&G;]%QRT&K4"Q&5<6++TLY77!*+!XBOKLF8PJ_AUPZ
M!\G864[!VY-S#$F2]L0@1-$>J(6@G=Z3-K/J[4\15-_=!-7O(ZB^L[V)JF]T
MH H=Z,4\.M"%2328>#5PR\JW7115=UQ$K750DXJ]8'P-9X!KL]>.Y=9NA>K^
MYXY1:*9$133-#&@JOJ![7!7LQ3<N8(W")^.ZQR@=\J6C4O%^:/@543.ZN8+(
M$19N8!*T+S(H0)\ 1S+_KUVW)JO49.2_HIC<E^2-!*$DR]LB(X&Q944AN.WF
M&QYF]#>/>N$$1S.;RM&\!8"Z@3Y%B0EI;$5U1*% A\N2%#3<@( #4:\%&2^'
M8ZK%>'!9,5B>,HUYAU#]=A.,K165RJVL4"O24:V%+)N$L;!L$0L[G0<?N/ZL
MO!JM^"KN1AT<Y7<=7(?8;2<D1$8(;@XAQ@$AM3[7VN40N608M"/!0F60);25
MH2'#<&*-;00+A9#&Q*?).Y$G1 2"*4DJ'/;ALD6)0M@K9&]0T<.1A-Y^7*P-
M)&H<:'*-I)?%CJQQUEO'5F7=JX9&,^-=U4<8X)='9*-1?"J"VCT[Q&V!(D)1
M&1[<F)Q6<%<!ZD[<.#"SD1@<;4!,#)-5(:%YX%9JFV=[H&? Y;%>9+QX3"LQ
M*_0ZSYWKX>1/J=//U.G7(LG@EM<P/$5T$S*,YTCZ.=XD)J%D*@%<E_@ZW=-S
MM)Z)+'@[]Z:_G5S9:8: JHB@'X(6GE$RR2)OY\1AW\<]K7;'895,F%>M3=17
MOM:^J%17'M>!J3_*0J$2F&0K=T=?-N'L53]@>-T)G275SE-WWT1#J?A^JBZH
MH7PK_7K+.T)G,I2A4JVG;S1):1U\P1$RF?^B0YG74D5R$#EE>#V?BI0J9 GX
M "%DZIB\D[T4#?1U[BH*\<*YL1)L4%WR63Y,,0J^E4ZC,F8D F96--F&Z524
M]#9=M8^@$IV8+YP@[H)5I-0A#0U;=I16528]Z@K-E_,%FJF&-Z DE+JBR5E;
MKT[#2!,).O'0-:?90(2V1":LF0[D0 P6H!C*;",K[B&N+S<[^<5%(#TT&\ 2
M$$0CFI[(8"=B!79[5V8DX<]&&(CF:Q%W?,QU$6CO<O1")JLT&86D$Z(H%;&I
M1.E*8$+(9&"2[!G7AE#P2WH-9T#W*2G6Z.Z^FN?NUK2">A+<K.V%K?$3C2<U
M$J@O*@N$L*JX"L%O538F8#Q9F47))!VH+2I,A98D?Y4I*84DUU3^A- SV5@%
MI9G,XR#U0]R61G@== +MD(3JH40Y<Z 9OH.9S!JQ62W(LD"?:##HY*#*CP<0
M08*B%4LM\9EZQW=WM7^S0^CT5OXMI0!D"^57>."O_J;/I6M45<'BO4VP^%Z"
MQ3N;8/%&)9E1)=F?1R4ASBIXE Z1V9,_.1<"KULXHM=31^&K-3.S%U\E!JNT
M0J[GN0/#%U*AND'0R8C@YQBY@#0!3!70-_BEADG4\U[YWN[V[O8BUHM_=!O_
MOS2PL>3G50U@WK@6Z;(I$Q5T0LE#M9'XFY S".U<O<P"D!7!=U(1%^2G4;(I
M-OB6("K SCXN]4O?12*PD%_E*%IC-F$/?\^6/8CM:2,*%)KVU^0W%:L4D4/.
M//E5IQX,APBJ"+P^'_Z5S79)M3^^8=2H4DK[(!AQSX%11FK5;*$[EWZET=YR
M1T%2H OGQ4)W]+=XY:&?V03[#"%&\ZU;H%@O'?/]K4L!-R,<5##*F3!MN=6=
MC/$O =K-<%JC ?BI<FR"TOH687+D^#*$_=["A/V"%VR!S2V<!&L)8]LTM6EJ
MT]2FJ4U3]][4%,ZV%QMGV[TXVW8WSK;[O!@M/MS6?Q;05O&AX.T?-,Z]+Q]K
MS=/:0?WKQ?%![>3<IQD<-PZVEMW[Q<=CWGWS[*\?'O_+^=G)\<'Q1?W0>__#
MN_A8]]Z?U9J'WMF1=WC<K!]<G#7/ESV@H[,F]EQK-+[63KS3>OWBN/$!AG!^
M<7;P^>/9R6&]>>Y=G'GOZ]['^LDA.VLL>TPYNW5!'6+C\K0NI,4*VP[\.VA<
M4BV[G3S5_C6(;["V/27JX&$F*QP:!& )6:Z# 8 2GH9A9J9G25^#<@ D\>V8
M@I9]Y" (@_85NA@ZWED[BV$A=U](7Q R@Q-;=3 <QA$D*G^*KP;>02_J!^T8
MT]4.KI*(CW<(F1:'\<T@Q7H.D7I!X^S[$/"\!0@4B?=IS%8, L.KW1$W$Q4E
M"3)8(!V02&Q'!@FP),7\C58T,H=*PVQ3&F8JJ?[P-O/?\J&'(WQC4GF;!^TM
M[PFT*-DM=5GP[LZ[IY+S?,(JVQX= =F$];*(1A,@PTCF7679,'W[_/E-F&;M
M.$@S'*&L/-[BPWX.RS5^Q@?\Y;D/MG+>.\/;V=E]N[WM?=DZW?+JO)4P@913
MOB40=X8SB!O(1%9OT/D9CPA>!K/,3!21=)'@,F4%IOP.1>I"1<L1W4YO3C_+
M#]F\\THU(!G-R45L)NH[2MB5Q&->PQ->C()8&3K*M]<-^E%O_-;[SM<"UB.U
M-#7L)R[LAD\2?OKO?[WXUXQ=&DU#;FBMUYLI%O7:5%\*!I;$-S2PO=*!D8)4
M=HZJ^M75)K%)R06^^$%,16X=' DE^2J&INA6X 21.%0$.)#Q6T+L]=:2N[[W
M*4S^&7M//@ A9/C4^S#JCWJ_ OAYMYN,O>:6]SD<PQD]"H"3  9QP"5?#W[T
M/LRX] IXT^U?2=PE')):?^R=!EP*C+<@VA!1^18AF(2W0Z .$#*02Y]7$P0A
MO@ $ 9!A6PHM*<6A0$I\9\2%(4Y=N+ !5#?J1I@F7Q Z-&[.W*=AE6[#=PG>
MO* K\6@74H@54;&Z*DM)4FG"U"J:54LW2?#-W\5RFKWK<&87X]-M<.5S+52
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M;'X<1 T.>(\BVL>#=IP,13XZ<::TDQ#*A)$K(\[X$Z!Y'@7LTS\6<: 5%$=
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M,"LZ"#9?9%E:NR 205TJJ$\&]>GX>X8TJ=._%Z(?(+;NW)$LP?2FU#]6FIF
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M,#(U,3$Q-U]L86(N>&UL4$L! A0#%     @ %8!86XY;6K&A$0  6?@  !4
M             ( !U2,! &-N<W M,C R-3$Q,3=?<')E+GAM;%!+!08
.!0 % $0!  "I-0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cns_def14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnsp-20251117.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729427</identifier>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-17" id="Fact000004">0001729427</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-17" id="xdx2ixbrl0010">DEF 14A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-17" id="Fact000011">CNS     Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="AsOf2025-11-17" id="Fact000012">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="AsOf2025-11-17" id="Fact000014">We do &lt;span id="xdx_908_eecd--AwardTmgMnpiCnsdrdFlag_dbT_c20251117__20251117_zFNJUWyRfjO"&gt;no&lt;/span&gt;t grant equity awards in anticipation of the
release of material nonpublic information, and do not time the public release of such information based on award grant dates.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="AsOf2025-11-17" id="Fact000015">true</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="AsOf2025-11-17" id="Fact000016">false</ecd:MnpiDiscTimedForCompValFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
